CN1231497C - Novel human protein with function for promoting mouse NIH/313 cell transformation and coding sequence thereof - Google Patents

Abstract

The present invention relates to a class of human proteins with a function of promoting 3T3 cell transformation, polynucleotide for coding the polypeptide, and a method for generating the polypeptide by a recombinant technology. The present invention also discloses an antagonist resisting the polypeptide and the therapeutic function of the antagonist. The present invention also discloses the applications of the polynucleotide for coding the class of human proteins with the function of promoting 3T3 cell transformation.

Description

New people's albumen and encoding sequence thereof with promotion mouse NIH/3T3 cell transformation function

Technical field

The invention belongs to biological technical field, specifically, the present invention relates to new coding and have the proteic polynucleotide of people that promote 3T3 cell transformation function, and the polypeptide of this polynucleotide encoding.The invention still further relates to the purposes and the preparation of these polynucleotide and polypeptide.

Background technology

The research of people's gene group is international focus at present, removes human chromosome DNA large scale sequencing, outside the method for expressed sequence order-checking (EST), also lacks the screening that begins from function and has the high-throughout method of functional gene.

Cancer is one of principal disease of harm humans health.In order to treat effectively and prophylaxis of tumours, people more and more pay close attention to genetic treatment of tumor at present.Therefore, this area presses for development research people albumen and the agonist/inhibitor thereof relevant with growth of cancer cells.

Summary of the invention

The purpose of this invention is to provide people's protein polypeptide that new the having of a class promote 3T3 cell transformation function with and fragment, analogue and derivative.

Another object of the present invention provides the polynucleotide of these polypeptide of coding.

Another object of the present invention provides the method for these polypeptide of production and the purposes of this polypeptide and encoding sequence.

In a first aspect of the present invention, novel isolated protein polypeptide with promotion 3T3 cell transformation function is provided, it comprises the polypeptide of the aminoacid sequence with the group of being selected from down: SEQ ID NO:3,6,9,12,15,18,21,24,27,30; Or its conservative property variation polypeptide or its active fragments or its reactive derivative.

Preferably, this polypeptide is the polypeptide with aminoacid sequence of the group of being selected from down: SEQ ID NO:3,6,9,12,15,18,21,24,27,30.

In a second aspect of the present invention, a kind of isolating polynucleotide are provided, it comprises a nucleotide sequence, and this nucleotide sequence is shown at least 85% homogeny with a kind of nucleotides sequence that is selected from down group: the polynucleotide with the protein polypeptide that promotes 3T3 cell transformation function that (a) coding is above-mentioned; (b) with polynucleotide (a) complementary polynucleotide.Preferably, the polypeptide of this polynucleotide encoding has the aminoacid sequence of the group of being selected from down: SEQ ID NO:3,6,9,12,15,18,21,24,27,30.More preferably, the sequence of these polynucleotide is selected from down group: SEQ ID NO:2,5,8,11,14,17,20,23,26,29 coding region sequence or full length sequence.

In a third aspect of the present invention, the carrier that contains above-mentioned polynucleotide is provided, and has been transformed or host cell of transduceing or the host cell that is directly transformed or transduce by above-mentioned polynucleotide by this carrier.

In a fourth aspect of the present invention, provide preparation to have the preparation method of the polypeptide of the protein-active that promotes 3T3 cell transformation function, this method comprises: (a) being fit to express under the proteic condition with promotion 3T3 cell transformation function, cultivate the above-mentioned host cell that is transformed or transduce; (b) from culture, isolate polypeptide with the protein-active that promotes 3T3 cell transformation function.

In a fifth aspect of the present invention, provide and the above-mentioned protein polypeptide specificity bonded antibody that promotes 3T3 cell transformation function that has.The nucleic acid molecule that can be used for detecting also is provided, and it contains, and continuous 10 Nucleotide are to full length nucleotide in the above-mentioned polynucleotide, and preferably it contains the about 15-1000 of a successive Nucleotide.

In a sixth aspect of the present invention, a kind of pharmaceutical composition is provided, it contains the protein polypeptide and the pharmaceutically acceptable carrier with promotion 3T3 cell transformation function of the present invention of safe and effective amount.These pharmaceutical compositions can be used for promoting the growth of cell.The present invention also provides a kind of pharmaceutical composition, it contain safe and effective amount at antagonist (as antibody) and the pharmaceutically acceptable carrier with the protein polypeptide that promotes 3T3 cell transformation function of the present invention.This pharmaceutical composition can be treated illnesss such as cancer and cellular abnormality propagation.

Others of the present invention are because disclosing of the technology of this paper is conspicuous to those skilled in the art.

Embodiment

The 3T3 cell is a kind of l cell (J.Cell.Biol., 17:299,1963) (being also referred to as the NIH/3T3 cell).In the cancer research field, often foreign gene (especially people's gene) is introduced the 3T3 cell, observe its situation that influences to the growth of 3T3 cell.It has been generally acknowledged that, to 3T3 cell growth (or vicious transformation or transfection) influential gene is cancer related gene, wherein to 3T3 cell growth or transform that inhibiting gene is arranged is cancer suppressor gene mostly, and to the growth of 3T3 cell or transform (former) oncogene that has the gene of promoter action to be mostly.

The present invention adopts large-scale cDNA clone transfection mouse embryo fibroblasts 3T3, has on the basis that promotes the growth effect in acquisition, proves new gene through order-checking, further obtains full length cDNA clone.DNA transfection evidence, the albumen with promotion 3T3 cell transformation function of the present invention has the effect that promotes that the clone forms, its promotion rate 〉=50% to the 3T3 cell.

As used herein, " isolating " is meant that material separates (if natural substance, primal environment promptly is a natural surroundings) from its primal environment.Do not have separation and purification as polynucleotide under the native state in the active somatic cell and polypeptide, but same polynucleotide or polypeptide as from native state with in other materials that exist separately, then for separation and purification.

As used herein, " isolating albumen or polypeptide with promotion 3T3 cell transformation function " is meant to have and promotes the protein polypeptide of 3T3 cell transformation function to be substantially free of natural relative other albumen, lipid, carbohydrate or other material.Those skilled in the art can have the albumen that promotes 3T3 cell transformation function with the purified technology of protein purifying of standard.Basically pure polypeptide can produce single master tape on non-reduced polyacrylamide gel.

Polypeptide of the present invention can be recombinant polypeptide, natural polypeptides, synthetic polypeptide, preferred recombinant polypeptide.Polypeptide of the present invention can be the product of natural purifying, or the product of chemosynthesis, or uses recombinant technology to produce from protokaryon or eucaryon host (for example, bacterium, yeast, higher plant, insect and mammalian cell).The host used according to the recombinant production scheme, polypeptide of the present invention can be glycosylated, maybe can be nonglycosylated.Polypeptide of the present invention also can comprise or not comprise initial methionine residues.

The present invention also comprises having the proteic fragment of people, derivative and the analogue that promotes 3T3 cell transformation function.As used herein, term " fragment ", " derivative " are meant with " analogue " and keep natural identical biological function or the active polypeptide of people's albumen that promotes 3T3 cell transformation function that have of the present invention basically.Polypeptide fragment of the present invention, derivative or analogue can be that (i) has one or more conservative or substituted polypeptide of non-conservation amino-acid residue (preferred conservative amino acid residue), and the amino-acid residue of such replacement can be also can not encoded by genetic code, or (ii) in one or more amino-acid residues, has a polypeptide of substituted radical, or (iii) mature polypeptide and another compound (such as the compound that prolongs the polypeptide transformation period, polyoxyethylene glycol for example) merge formed polypeptide, or (iv) additional aminoacid sequence is fused to this peptide sequence and the polypeptide that forms (as leader sequence or secretion sequence or be used for the sequence or the proteinogen sequence of this polypeptide of purifying).According to the instruction of this paper, these fragments, derivative and analogue belong to the known scope of those skilled in the art.

Polynucleotide of the present invention can be dna form or rna form.Dna form comprises the DNA of cDNA, genomic dna or synthetic.DNA can be strand or double-stranded.DNA can be coding strand or noncoding strand.Be example with FP18315 albumen (in this application, its clone numbering is adopted in proteinic name), the coding region sequence of encoding mature polypeptide can be identical with the coding region sequence shown in the SEQ ID NO:2 or the varient of degeneracy.As used herein, " varient of degeneracy " is meant that for FP18315 coding has the protein of SEQ ID NO:3, but with the differentiated nucleotide sequence of coding region sequence shown in the SEQ ID NO:2.Be example with LP2209 albumen again, the coding region sequence of encoding mature polypeptide can be identical with the coding region sequence shown in the SEQ ID NO:5 or the varient of degeneracy.As used herein, " varient of degeneracy " is meant that for LP2209 coding has the protein of SEQ ID NO:6, but with the differentiated nucleotide sequence of coding region sequence shown in the SEQ ID NO:5.Other have the albumen that promotes 3T3 cell transformation function for the present invention, and the rest may be inferred.

The polynucleotide of encoding mature polypeptide comprise: the encoding sequence of an encoding mature polypeptide; The encoding sequence of mature polypeptide and various additional code sequence: encoding sequence of mature polypeptide (with optional additional code sequence) and non-coding sequence.

Term " polynucleotide of coded polypeptide " can be the polynucleotide that comprise this polypeptide of encoding, and also can be the polynucleotide that also comprise additional code and/or non-coding sequence.

The invention still further relates to the varient of above-mentioned polynucleotide, its coding has the polypeptide of identical aminoacid sequence or fragment, analogue and the derivative of polypeptide with the present invention.The varient of these polynucleotide can be the allelic variant of natural generation or the varient that non-natural takes place.These nucleotide diversity bodies comprise and replace varient, deletion mutation body and insert varient.As known in the art, allelic variant is the replacement form of polynucleotide, and it may be replacement, disappearance or the insertion of one or more Nucleotide, but can be from not changing the function of its encoded polypeptides in fact.

The invention still further relates to and above-mentioned sequence hybridization and two sequences between have at least 50%, preferably at least 70%, the polynucleotide of at least 80% homogeny more preferably.The present invention be more particularly directed under stringent condition and the interfertile polynucleotide of polynucleotide of the present invention.In the present invention, " stringent condition " is meant: (1) than hybridization under low ionic strength and the comparatively high temps and wash-out, as 0.2 * SSC, and 0.1%SDS, 60 ℃; Or (2) hybridization the time is added with denaturing agent, as 50% (v/v) methane amide, 0.1% calf serum/0.1%Ficoll, 42 ℃ etc.; Or (3) only at the homogeny between the two sequences at least more than 95%, be more preferably 97% and just hybridize when above.And the polypeptide of interfertile polynucleotide encoding has identical biological function and activity with the mature polypeptide shown in the SEQ IDNO:3 (is example with FP18315 albumen).

The invention still further relates to nucleic acid fragment with above-mentioned sequence hybridization.As used herein, the length of " nucleic acid fragment " contains 15 Nucleotide at least, better is at least 30 Nucleotide, is more preferably at least 50 Nucleotide, preferably more than at least 100 Nucleotide.The amplification technique (as PCR) that nucleic acid fragment can be used for nucleic acid has the proteic polynucleotide that promotes 3T3 cell transformation function to determine and/or to separate coding.

Polypeptide among the present invention and polynucleotide preferably provide with isolating form, more preferably are purified to homogeneous.

Dna sequence dna of the present invention can obtain with several method.For example, with hybridization technique DNA isolation well known in the art.These technology including, but not limited to: 1) with probe and genome or the hybridization of cDNA library to detect homology nucleotide sequence and 2) antibody screening of expression library to be to detect the dna fragmentation of the clone with common structure feature.

Coding has the proteic specific DNA fragment sequence that promotes 3T3 cell transformation function and produces also and can obtain with following method: 1) separate double chain DNA sequence from genomic dna; 2) the chemical synthesising DNA sequence is to obtain the double-stranded DNA of required polypeptide.

When the whole aminoacid sequence of the polypeptide product of needs was known, the direct chemical of dna sequence dna is synthetic to be the method for often selecting for use.When if required amino acid whose whole sequence is not known, the direct chemical of dna sequence dna is synthetic to be impossible, and the method for selecting for use is the separation of cDNA sequence.The standard method that separates interested cDNA is from the donorcells separating mRNA of this gene of high expression level and carries out reverse transcription, forms plasmid or phage cDNA library.Extract the existing multiple proven technique of method of mRNA, test kit also can obtain (Qiagene) from commercial channels.And the construction cDNA library also is usual method (Sambrook, et al., Molecular Cloning, A Laboratory Manual, Cold Spring HarborLaboratory.New York, 1989).Also can obtain the cDNA library of commercial offers, as the different cDNA library of Clontech company.When being used in combination the polymeric enzyme reaction technology, even few expression product also can be cloned.

Available ordinary method is screened gene of the present invention from these cDNA libraries.These methods include, but is not limited to: (1) DNA-DNA or DNA-RNA hybridization; (2) function of marker gene occurs or forfeiture; (3) measure level with the proteic transcript that promotes 3T3 cell transformation function; (4), detect the protein product of genetic expression by immunological technique or mensuration biologic activity.Aforesaid method can singly be used, but also several different methods combined utilization.

In (1) kind method, hybridizing used probe is and any a part of homology of polynucleotide of the present invention that at least 15 Nucleotide of its length better are at least 30 Nucleotide, are more preferably at least 50 Nucleotide, preferably at least 100 Nucleotide.In addition, the length of probe within 2kb, preferably is within the 1kb usually.Probe used herein is the dna sequence dna of chemosynthesis on the basis of gene DNA sequence information of the present invention normally.Gene of the present invention itself or fragment are certainly as probe.The mark of dna probe can be used radio isotope, fluorescein or enzyme (as alkaline phosphatase) etc.

In (4) kind method, detect protein product and can use immunological technique such as Western blotting, radioimmunoprecipitation, enzyme-linked immunosorbent assay (ELISA) etc. with the protein gene expression that promotes 3T3 cell transformation function.

Use method (Saiki, the et al.Science 1985 of round pcr DNA amplification/RNA; 230:1350-1354) be optimized for acquisition gene of the present invention.When particularly being difficult to obtain the cDNA of total length from the library, can preferably use RACE method (the terminal rapid amplifying method of RACE-cDNA), the primer that is used for PCR can suitably be selected according to sequence information of the present invention disclosed herein, and available ordinary method is synthetic.Available ordinary method is as the DNA/RNA fragment by gel electrophoresis separation and purifying amplification.

The gene of the present invention that obtains as mentioned above, perhaps the available ordinary method of mensuration of the nucleotide sequence of various dna fragmentations etc. such as dideoxy chain termination (Sanger et al.PNAS, 1977,74:5463-5467).This class nucleotide sequencing is available commercial sequencing kit etc. also.In order to obtain the cDNA sequence of total length, order-checking need be carried out repeatedly.Sometimes need to measure a plurality of clones' cDNA sequence, just can be spliced into the cDNA sequence of total length.

The present invention also relates to comprise the carrier of polynucleotide of the present invention, and with carrier of the present invention or have the host cell that the albumen coded sequence that promotes 3T3 cell transformation function produces through genetically engineered, and the method that produces polypeptide of the present invention through recombinant technology.

Recombinant DNA technology (Science, 1984 by routine; 224:1431), can utilize polymerized nucleoside acid sequence of the present invention to can be used to express or produce the protein polypeptide that promotes 3T3 cell transformation function that has of reorganization.In general following steps are arranged:

(1). have the proteic polynucleotide of people (or varient) that promote 3T3 cell transformation function with coding of the present invention, or transform or the transduction proper host cell with the recombinant expression vector that contains these polynucleotide;

(2). the host cell of in suitable medium, cultivating;

(3). separation, protein purification from substratum or cell.

Among the present invention, the people's albumen polynucleotide sequence with promotion 3T3 cell transformation function can be inserted in the recombinant expression vector.Term " recombinant expression vector " refers to that bacterial plasmid well known in the art, phage, yeast plasmid, vegetable cell virus, mammalian cell virus are as adenovirus, retrovirus or other carriers.The carrier of Shi Yonging includes but not limited in the present invention: and the expression vector based on T7 of in bacterium, expressing (Rosenberg, et al.Gene, 1987,56:125); The pMSXND expression vector of in mammalian cell, expressing (Lee and Nathans, J Bio Chem.263:3521,1988) and at the carrier that derives from baculovirus of expressed in insect cells.In a word, as long as can duplicate in host and stablize, any plasmid and carrier can be used.A key character of expression vector is to contain replication orgin, promotor, marker gene and translation controlling elements usually.

Method well-known to those having ordinary skill in the art can be used to make up contain and has people's encoding histone dna sequence dna of promoting 3T3 cell transformation function and suitable transcribing/translate the expression vector of control signal.These methods comprise (Sambroook, et al) such as extracorporeal recombinant DNA technology, DNA synthetic technology, the interior recombinant technologys of body.Described dna sequence dna can effectively be connected on the suitable promotor in the expression vector, and is synthetic to instruct mRNA.The representative example of these promotors has: colibacillary lac or trp promotor; Lambda particles phage PL promotor; Eukaryotic promoter comprises CMV immediate early promoter, early stage and late period SV40 promotor and some other known may command gene expression promoter in protokaryon or eukaryotic cell or its virus.Expression vector also comprises ribosome bind site and the transcription terminator that translation initiation is used.

In addition, expression vector preferably comprises one or more selected markers, to be provided for selecting the phenotypic character of transformed host cells, cultivate Tetrahydrofolate dehydrogenase, neomycin resistance and the green fluorescent protein (GFP) of usefulness as eukaryotic cell, or be used for colibacillary tsiklomitsin or amicillin resistance.

Comprise the carrier of above-mentioned suitable dna sequence dna and suitable promotor or control sequence, can be used to transform appropriate host cell, so that it can marking protein.

Host cell can be a prokaryotic cell prokaryocyte, as bacterial cell; Or eukaryotic cell such as low, as yeast cell; Or higher eucaryotic cells, as mammalian cell.Representative example has: intestinal bacteria, streptomyces; The bacterial cell of Salmonella typhimurium; Fungal cell such as yeast; Vegetable cell; The insect cell of fruit bat S2 or Sf9; The zooblast of CHO, COS or Bowes melanoma cells etc.

When polynucleotide of the present invention are expressed in higher eucaryotic cells, be enhanced if will make to transcribe when in carrier, inserting enhancer sequence.Enhanser is the cis acting factor of DNA, and nearly 10 to 300 base pairs act on promotor transcribing with enhancing gene usually.Can for example be included in the SV40 enhanser of 100 to 270 base pairs of replication origin side in late period one, at the polyoma enhanser of replication origin side in late period one and adenovirus enhanser etc.

Persons skilled in the art all know how to select appropriate carriers, promotor, enhanser and host cell.

Can carry out with routine techniques well known to those skilled in the art with the recombinant DNA transformed host cell.When the host was prokaryotic organism such as intestinal bacteria, the competent cell that can absorb DNA can be used CaCl in exponential growth after date results ₂Method is handled, and used step is well-known in this area.Alternative is to use MgCl ₂If desired, transforming also the method for available electroporation carries out.When the host is an eukaryote, can select following DNA transfection method for use: coprecipitation of calcium phosphate method, conventional mechanical method such as microinjection, electroporation, liposome packing etc.

The transformant that obtains can be cultivated with ordinary method, expresses the polypeptide of coded by said gene of the present invention.According to used host cell, used substratum can be selected from various conventional substratum in the cultivation.Under the condition that is suitable for the host cell growth, cultivate.After host cell grows into suitable cell density, induce the promotor of selection with suitable method (as temperature transition or chemical induction), cell is cultivated for some time again.

Recombinant polypeptide in the above methods can wrap by in the daughter cell, extracellular or on cytolemma, express or be secreted into the extracellular.If desired, can utilize its physics, the separating by various separation methods with other characteristic and the albumen of purification of Recombinant of chemistry.These methods are well-known to those skilled in the art.The example of these methods includes, but are not limited to: conventional renaturation handles, with protein precipitant handle (salt analysis method), centrifugal, the broken bacterium of infiltration, superly handle, the combination of super centrifugal, sieve chromatography (gel-filtration), adsorption chromatography, ion exchange chromatography, high performance liquid chromatography (HPLC) and other various liquid chromatography (LC) technology and these methods.

Having of reorganization promotes the people's albumen or the polypeptide of 3T3 cell transformation function to be of use in many ways.These purposes include, but is not limited to: directly have the disease due to the low or forfeiture of the protein function that promotes 3T3 cell transformation function as pharmacological agent and be used to screen and promote or antagonism has antibody, polypeptide or other part of the protein function that promotes 3T3 cell transformation function.For example, this antibody can be used for treating cancer or cellular abnormality propagation.The peptide molecule that can suppress or stimulate people's protein function that can be used for seeking therapeutic value with recombinant expressed protein screening peptide library of the present invention with promotion 3T3 cell transformation function.

The present invention also provides screening of medicaments to improve (agonist) or check the method that (antagonist) has the proteic medicament of people that promotes 3T3 cell transformation function to identify.Agonist improves and to have the people's albumen that promotes 3T3 cell transformation function biological function such as stimulate cellular proliferation, and antagonist prevention disorder such as the various cancer relevant with cell hyperproliferation with treatment.

Have the proteic antagonist of people that promotes 3T3 cell transformation function and comprise antibody, compound, acceptor disappearance thing and the analogue etc. that filter out.Have the proteic antagonist of people that promotes 3T3 cell transformation function and can and eliminate its function with people's protein binding with promotion 3T3 cell transformation function, or suppress to have the proteic generation of people that promotes 3T3 cell transformation function, or combine with the avtive spot of polypeptide and to make polypeptide can not bring into play biological function.Have and promote the proteic antagonist of people of 3T3 cell transformation function to can be used for therepic use.

In screening during as the compound of antagonist, can add in the bioanalysis mensuration having the albumen that promotes 3T3 cell transformation function, the albumen and the interaction between its acceptor that have promotion 3T3 cell transformation function by the mensuration compounds affect determine whether compound is antagonist.With the same quadrat method of above-mentioned SCREENED COMPOUND, can filter out the acceptor disappearance thing and the analogue of antagonist action.

The proteic antagonist of the present invention can be directly used in disease treatment, for example, and various malignant tumours and cellular abnormality propagation etc.

Polypeptide of the present invention, and fragment, derivative, analogue or their cell can be used as antigen to produce antibody.These antibody can be polyclone or monoclonal antibody.Polyclonal antibody can obtain by the method with this polypeptide direct injection animal.The technology of preparation monoclonal antibody comprises hybridoma technology, three knurl technology, people B-quadroma technology, EBV-hybridoma technology etc.

Can be with polypeptide of the present invention and antagonist and suitable pharmaceutical carrier combination back use.These carriers can be water, glucose, ethanol, salt, damping fluid, glycerine and their combination.Composition comprises the polypeptide or the antagonist of safe and effective amount and carrier and the vehicle that does not influence effect of drugs.These compositions can be used as medicine and are used for disease treatment.

The present invention also provides medicine box or the test kit that contains one or more containers, and one or more medicinal compositions compositions of the present invention are housed in the container.With these containers, can have by the given indicative prompting of government authorities of making, using or selling medicine or biological products, the government authorities that this prompting reflects production, uses or sells permits it to use on human body.In addition, polypeptide of the present invention can be used in combination with other treatment compound.

Pharmaceutical composition can be with mode administration easily, as by in part, intravenously, intraperitoneal, intramuscular, subcutaneous, the nose or the route of administration of intracutaneous.Have the albumen or its specific antibody that promote 3T3 cell transformation function, can come administration by the amount that treats and/or prevents concrete indication effectively.Be applied to having of patient and promote the proteic amount and the dosage range of 3T3 cell transformation function will depend on many factors, as administering mode, person's to be treated healthiness condition and diagnostician's judgement.

Have and promote the proteic polynucleotide of people of 3T3 cell transformation function also to can be used for multiple therapeutic purpose.Gene therapy technology can be used for treating since have that the proteic nothing that promotes 3T3 cell transformation function is expressed or unusual/non-activity have cell development or a metabolic disturbance due to the proteic expression that promotes 3T3 cell transformation function.The gene therapy vector (as virus vector) of reorganization can be designed to express the albumen that promotes 3T3 cell transformation function that has of variation, to suppress the endogenic protein-active that promotes 3T3 cell transformation function that has.For example, a kind of albumen that promotes 3T3 cell transformation function that has of variation can be the albumen with promotion 3T3 cell transformation function that shortens, lacked signal conduction function territory, though can combine with the substrate in downstream, lacks signaling activity.Therefore the gene therapy vector of reorganization can be used for treating and has the protein expression that promotes 3T3 cell transformation function or the disease of active caused by abnormal.Deriving from the expression vector of virus such as retrovirus, adenovirus, adeno-associated virus (AAV), hsv, parvovirus etc. can be used for having and promotes the protein gene of 3T3 cell transformation function to be transferred in the cell.The method that structure carries the recombinant viral vector with the protein gene that promotes 3T3 cell transformation function is found in existing document (Sambrook, et al.).Reorganization has the people's protein gene that promotes 3T3 cell transformation function and can be packaged in the liposome and be transferred in the cell in addition.

Inhibition has the oligonucleotide (comprising sense-rna and DNA) of the people's protein mRNA that promotes 3T3 cell transformation function and ribozyme also within the scope of the invention.Ribozyme is the enzyme sample RNA molecule that a kind of energy specificity is decomposed specific RNA, and its mechanism of action is to carry out the endonuclease effect after ribozyme molecule and the hybridization of complementary target RNA-specific.The RNA of antisense and DNA and ribozyme can obtain with existing any RNA or DNA synthetic technology, as the technology widespread use of solid phase phosphoamide chemical synthesis synthetic oligonucleotide.Antisense rna molecule can be transcribed acquisition by the dna sequence dna of this RNA that encodes in external or body.This dna sequence dna has been incorporated into the downstream of rna polymerase promoter of carrier.In order to increase the stability of nucleic acid molecule, available several different methods is modified it, and as increasing the sequence length of both sides, the connection between the ribonucleoside is used phosphoric acid thioester bond or peptide bond but not phosphodiester bond.

Polynucleotide imports tissue or intracellular method comprises: directly be injected into polynucleotide in the in-vivo tissue; Or external by carrier (as virus, phage or plasmid etc.) earlier with the polynucleotide transfered cell in, again cell is transplanted in the body etc.Because albumen of the present invention has the function that promotes the 3T3 cell transformation, so the antisense sequences of albumen coded sequence of the present invention, can be introduced into cell to suppress the abnormality proliferation (as canceration) of cell.

The present invention also provides at the antibody with the people's proteantigen determinant that promotes 3T3 cell transformation function.These antibody include, but is not limited to: the fragment that polyclonal antibody, monoclonal antibody, chimeric antibody, single-chain antibody, Fab fragment and Fab expression library produce.

The anti-proteic antibody of people with promotion 3T3 cell transformation function can be used in the immunohistochemistry technology, detects the people's albumen that promotes 3T3 cell transformation function that has in the biopsy specimen.

The also available labelled with radioisotope of the protein bound monoclonal antibody of people with having promotion 3T3 cell transformation function injects in the body and can follow the tracks of its position and distribution.This radiolabeled antibody can be used as a kind of atraumatic diagnostic method and is used for the location of tumour cell and has judged whether transfer.

Antibody among the present invention can be used for treating or preventing and have the relevant disease of people's albumen of promotion 3T3 cell transformation function.The antibody that gives suitable dosage can be blocked proteic generation of people or the activity with promotion 3T3 cell transformation function, thus the abnormality proliferation of the growth of anticancer and/or cell.

Antibody also can be used for designing the immunotoxin at a certain privileged sites in the body.As have the people's albumen high-affinity that promotes 3T3 cell transformation function monoclonal antibody can with bacterium or plant poison (as diphtheria toxin, ricin, abrine etc.) covalent attachment.A kind of usual method is with sulfydryl linking agent such as SPDP, attacks the amino of antibody, by the exchange of disulfide linkage, toxin is incorporated on the antibody, and this hybrid antibody can be used for killing relevant positive cell (as cancer cells).

Available people's albumen or the polypeptide immune animal of the production of polyclonal antibody with promotion 3T3 cell transformation function, as rabbit, mouse, rat etc.Multiple adjuvant can be used for the enhancing immunity reaction, includes but not limited to freund's adjuvant etc.

Have promote 3T3 cell transformation function people's protein monoclonal antibody can with hybridoma technology production (Kohler andMilstein.Nature, 1975,256:495-497).With the variable region bonded chimeric antibody in human constant region and inhuman source can with existing technology production (Morrison et al, PNAS, 1985,81:6851).And the technology of existing manufacture order chain antibody (U.S.Pat No.4946778) also can be used for producing the anti-proteic single-chain antibody of people that promotes 3T3 cell transformation function that has.

Can with have the protein bound peptide molecule of people that promotes 3T3 cell transformation function and can be incorporated into the rondom polypeptide storehouse that solid formation forms by the various amino acid that may make up by screening and obtain.During screening, must promote people's protein molecular of 3T3 cell transformation function to carry out mark to having.

The invention still further relates to quantitatively and detection and localization has the diagnostic testing process of people's protein level of promotion 3T3 cell transformation function.These tests are known in the art, and comprise that FISH measures and radioimmunoassay.That is detected in the test has a protein level that promotes 3T3 cell transformation function, can have the importance of albumen in various diseases that promotes 3T3 cell transformation function with laying down a definition and be used to diagnose to have the disease that the albumen that promotes 3T3 cell transformation function works.

Proteic polynucleotide with promotion 3T3 cell transformation function can be used for having the diagnosis and the treatment of the protein related diseases that promotes 3T3 cell transformation function.Aspect diagnosis, have the proteic polynucleotide that promotes 3T3 cell transformation function can be used for detecting have promote 3T3 cell transformation function proteic expression whether or under morbid state, have an abnormal exprssion that promotes 3T3 cell transformation function.As the protein D NA sequence with promotion 3T3 cell transformation function can be used for that the hybridization of biopsy specimen is had the proteic abnormal expression that promotes 3T3 cell transformation function with judgement.Hybridization technique comprises the Southern blotting, Northern blotting, in situ hybridization etc.These technological methods all are disclosed mature technologies, and relevant test kit all can obtain from commercial channels.Part or all of polynucleotide of the present invention can be used as probe stationary on microarray (Microarray) or DNA chip (being gene chip), is used for analyzing the differential expression analysis and the gene diagnosis of tissue gene.Carry out RNA-polymerase chain reaction (RT-PCR) amplification in vitro with the special primer of albumen and also can detect proteic transcription product with promotion 3T3 cell transformation function with promotion 3T3 cell transformation function.

The sudden change that detection has the protein gene that promotes 3T3 cell transformation function also can be used for diagnosing the relevant disease of albumen with promotion 3T3 cell transformation function.Form with the protein mutation that promotes 3T3 cell transformation function comprises that to have point mutation that the protein D NA sequence that promotes 3T3 cell transformation function compares, transposition, disappearance, reorganization and other any unusual etc. with normal wild type.Available existing technology such as Southern blotting, dna sequence analysis, PCR and in situ hybridization detect sudden change.In addition, sudden change might influence proteic expression, therefore can judge indirectly that with Northern blotting, Western blotting gene has or not sudden change.

Sequence of the present invention identifies it also is valuable to karyomit(e).These sequences can be specifically at certain bar human chromosome particular location and and can with its hybridization.At present, need to identify the concrete site of each gene on the karyomit(e).Yet have only chromosomal marker thing seldom to can be used for the marker chromosomes position now based on actual sequence data (repetition polymorphism).For these sequences are associated with disease related gene.The first step is positioned dna sequence dna of the present invention on the karyomit(e) exactly.

In brief, prepare PCR primer (preferred 15-35bp), sequence can be positioned on the karyomit(e) according to cDNA.Then, these primers are used for the somatocyte hybrid cell that the PCR screening contains each bar human chromosome.Have only those hybrid cells that contain corresponding to the people's gene of primer can produce the fragment of amplification.

The PCR localization method of somatocyte hybrid cell is that DNA is navigated to concrete chromosomal quick method.Use Oligonucleolide primers of the present invention,, can utilize one group to realize inferior location from specific chromosomal fragment or a large amount of genomic clone by similar approach.Other the similar strategy that can be used for chromosomal localization comprises in situ hybridization, uses the karyomit(e) prescreen and the hybridization preliminary election of the airflow classification of mark, thereby makes up the special cDNA storehouse of karyomit(e).

The cDNA clone is carried out fluorescence in situ hybridization (FISH) with Metaphase Chromosome, can in a step, accurately carry out chromosomal localization.The summary of this technology is referring to Verma etc., Human Chromosomes:a Manual of BasicTechniques, Pergamon Press, New York (1988).

In case sequence is positioned to chromosome position accurately, the physical location of this sequence on karyomit(e) just can be associated with the gene map data.These data for example are found in, V.Mckusick, Mendelian Inheritance in Man (can by with the online acquisition of Johns Hopkins University Welch Medical Library).Can pass through linkage analysis then, determine gene and navigated to relation between the disease on the chromosomal region already.

Then, need to measure ill and not cDNA between diseased individuals or genome sequence difference.If observe certain sudden change in some or all of diseased individuals, and this sudden change is not observed in any normal individual, then this sudden change may be the cause of disease of disease.More ill and diseased individuals not is usually directed at first seek the variation of structure in the karyomit(e), as from the horizontal visible of karyomit(e) or use based on detectable disappearance of the PCR of cDNA sequence or transposition.

Pyrenoids thuja acid full length sequence or its fragment with promotion 3T3 cell transformation function of the present invention can obtain with the method for pcr amplification method, recombination method or synthetic usually.For the pcr amplification method, can be disclosed according to the present invention about nucleotide sequence, especially open reading frame sequence designs primer, and with commercially available cDNA storehouse or by the prepared cDNA storehouse of ordinary method well known by persons skilled in the art as template, amplification and must relevant sequence.When sequence is longer, usually needs to carry out twice or pcr amplification repeatedly, and then the fragment that each time amplifies is stitched together by proper order.

In case obtained relevant sequence, just can obtain relevant sequence in large quantity with recombination method.This normally is cloned into carrier with it, changes cell again over to, separates obtaining relevant sequence then from the host cell after the propagation by ordinary method.

In addition, also the method for available synthetic is synthesized relevant sequence, especially fragment length more in short-term.Usually, by first synthetic a plurality of small segments, and then connect and to obtain the very long fragment of sequence.

At present, can be fully come the dna sequence dna of code book invention albumen (or its fragment, or derivatives thereof) by chemosynthesis.This dna sequence dna can be introduced then in the various dna moleculars (as carrier) and cell in this area.In addition, also can will suddenly change and introduce in the protein sequence of the present invention by chemosynthesis.

Because the albumen with promotion 3T3 cell transformation function of the present invention has the natural acid sequence that is derived from the people, therefore, compare with the albumen of the same clan that derives from other species, estimate to have higher active and/or lower side effect (for example in the intravital immunogenicity of people lower or do not have) being applied to man-hour.

Below in conjunction with specific embodiment, further set forth the present invention.Should be understood that these embodiment only to be used to the present invention is described and be not used in and limit the scope of the invention.The experimental technique of unreceipted actual conditions in the following example, usually according to people such as normal condition such as Sambrook, molecular cloning: laboratory manual (New York:Cold Spring Harbor LaboratoryPress, 1989) condition described in, or the condition of advising according to manufacturer.Notice that in Nucleotide and amino acid composite sequence, what (1) provided is the position that initial sum stops first Nucleotide of coding, (2) molecular weight unit is dalton.

The acquisition of embodiment 1:cDNA gene and the promoter action that mouse NIH/3T3 cell clone is formed

FP18315 comes from the human fetal cDNA library that makes up with ordinary method: LP2209, LP2570, LP3317, LP3428, LP4947, LP5553, LP6347, LP8067 and LP8151 come from the normal hepatocytes cDNA library that makes up with ordinary method.Get fetal tissue (FP clone) or normal liver tissue (LP clone), (GIBCO BRL company) extracts total RNA by manufacturer's specification sheets with Trizol reagent, extracts mRNA with the mRNA test kit (Pharmacia company) of purifying.Make up the cDNA library of above-mentioned mRNA with pCMV-script TMXRcDNA library construction test kit (Stratagene company).Wherein ThermoScript II is used MMLV-RT-Superscript II (GIBCO BRL) instead, and reverse transcription reaction carries out at 42 ℃.Transform XL 10-Gold recipient cell, obtained the cDNA library of 1 * 106cfu/ μ g titre.The first round is picking cDNA clone at random, is probe with high abundance cDNA clone with the cDNA clone who has proved anticancer growth function thereafter, screening by hybridization cDNA library, weak positive and negative clone of picking.With Qiagen 96 orifice plate plasmid extraction test kits, carry out the extraction of plasmid DNA by shop instruction.Plasmid DNA and empty carrier transfection simultaneously mouse NIH/3T3 cell.After the 100ng DNA alcohol precipitation drying, add 6 μ l H2O dissolving, treat transfection.Add 0.74 μ l liposome and 9.3 μ l serum-free mediums in every part of DNA sample, behind the mixing, room temperature was placed 10 minutes.Add 150 μ l serum-free mediums in every pipe, divide equally and add 3 holes and grow in the mouse NIH/3T3 cell of 96 orifice plates, placed 2 hours for 37 ℃, every hole adds 50 μ l serum-free mediums again, 37 ℃ 24 hours.Every hole is changed 100 μ l and is trained liquid entirely, 37 ℃ 24 hours, change the full training liquid 100 μ l that contain G418,37 ℃ 24-48 hour, the limit is observed, the training liquid that G418 concentration does not wait is changed on the limit.After about 2-3 time, there is the clone to form up to the microscopy cell, counting.Find that above-mentioned clone has the cell clone of promotion formation effect, the result is as shown in the table.

CDNA clone's transfectional cell (3T3) clone formation situation

CDNA clones title	CDNA clones number (three repetitions)			Empty carrier clone number (three repetitions)
							FP18315	84	88	78	39	41	38
LP2209	62	68	63	4	9	13
							LP2570	68	76	83	22	25	29
LP3317	61	56	52	35	32	38
							LP3428	68	60	63	37	35	30
LP4947	50	51	40	29	36	31
							LP5553	45	48	50	20	15	17
LP6347	48	53	50	27	30	34
							LP8067	66	62	65	41	36	30
LP8151	61	63	60	30	45	40

The cDNA clone is adopted two deoxidation cessation method, on the ABI377 automatic dna sequencer, measure the nucleotide sequence of the nearly 500bp of one end.After the analysis, be defined as novel gene cloning, carry out the other end order-checking, do not obtain full length cDNA sequence yet, the design primer checks order once more, up to obtaining full length sequence (SEQ ID NO:1,4,7,10,13,16,19,22,25,28).

Embodiment 2: PCR obtains full-length gene from placenta or normal hepatocytes cDNA:

Get fetal tissue (FP clone) or normal liver tissue (LP clone), (GIBCO BRL company) extracts total RNA by manufacturer's specification sheets with Trizol reagent, extracts mRNA with the mRNA test kit (Pharmacia company) of purifying.With MMLV-RT-Superscript II (GIBCO BRL), ThermoScript II is carried out reverse transcription reaction at 42 ℃, obtains placenta or fetus cDNA.Utilize the special primer (as shown in the table) of each gene, by 97 ℃ of 3 ' 1 circulation.94 ℃ 30 " 60 ℃ 30 " 72 ℃ of 1 ' 35 circulation, pcr amplification is carried out in 72 ℃ of 10 ' 1 circulation, and acquisition contains the amplified production of each protein gene of complete open reading frame sequence.Amplified production is through sequence verification, and the sequence that records with embodiment 1 conforms to, and changes amplified production over to host cell with routine techniques subsequently, obtains recombinant protein (SEQ ID NO:3,6,9,12,15,18,21,24,27,30).

Gene specific primer

Clone's title	Special primer 1 (5 ' → 3 ')	SEQ ID NO	Special primer 2 (3 ' → 5 ')	SEQ ID NO
					FP18315	(73)GGCCAGCTCATGGTATCTCC	31	ATGAACCCTCTGACTCCGTCC(1884)	32
LP2209	(101)CAGAAACCTGGGGTAAGCAA	33	TACAAATCACGGGAAAAGTACG(812)	34
					LP2570	(33)GATGATGCTGCCAAGTTATTCA	35	ATCCCCATAGACATCCTTACCG(1729)	36
LP3317	(57)CTGGAGGGAGATCACAAAACA	37	ATGAAGCACTGGTGGGTGATAC(1102)	38
					LP3428	(33)CCCGTCTGGGATGTGAGG	39	GCTCTTTGTGGGTTCTTACTAG(1222)	40
LP4947	(22)TTCATACTTGGTGCGCTGTG	41	GAGGGAACAAAGCTAACGG(2058)	42
					LP5553	(94)GATTCTGCCCATGTGCTCC	43	TCCTTTATTTCGTCTTCCTTGC(1901)	44
LP6347	(138)TAGCTGGTTGCTAGAGTTACGG	45	TTTCCTTTATTCGGCACGTT(1899)	46
					LP8067	(19)CGGCAGACTGGGGTTGGT	47	TTTATTTCGCGGTCGCGT(15548)	48
LP8151	(27)GGGTGTTGCTGTCATCTCCA	49	TTCTCCAAACCTCCCTCACC(1629)	50

Annotate: in the bracket is the correspondence position of primer in each gene DNA sequence.

Embodiment 3:cDNA cloned sequence is analyzed

1.FP18315

A: nucleotide sequence (SEQ ID NO:1) length: 2032 bases

B: aminoacid sequence (SEQ ID NO:3) length: 117 amino acid

C. Nucleotide and amino acid composite sequence (SEQ ID NO:2) clone number and protein name: FP18315 start code: 898ATG stops coding: 1249TAG protein molecular weight: 12585.84

2.LP2209

A: nucleotide sequence (SEQ ID NO:4) length: 926 bases

B: aminoacid sequence (SEQ ID NO:6) length: 70 amino acid

C. Nucleotide and amino acid composite sequence (SEQ ID NO:5) clone number and protein name: LP2209 start code: 430ATG stops coding: 640TGA protein molecular weight: 7837.38

3.LP2570

A: nucleotide sequence (SEQ ID NO:7) length: 1814 bases

B: aminoacid sequence (SEQ ID NO:9) length: 117 amino acid

C. Nucleotide and amino acid composite sequence (SEQ ID NO:8) clone number and protein name: LP2570 start code: 1001 ATG stop coding: 1352 TAA protein molecular weights: 12882.88

4.LP2317

A: nucleotide sequence (SEQ ID NO:10) length: 1199 bases

B: aminoacid sequence (SEQ ID NO:12) length: 103 amino acid

C. Nucleotide and amino acid composite sequence (SEQ ID NO:11) clone number and protein name: LP3317 start code: 217 ATG stop coding: 526 TAA protein molecular weights: 11308.46

5.LP3428

A: nucleotide sequence (SEQ ID NO:13) length: 1269 bases

B: aminoacid sequence (SEQ ID NO:15) length: 80 amino acid

C. Nucleotide and amino acid composite sequence (SEQ ID NO:14) clone number and protein name: LP3428 start code: 978 ATG stop coding: 1218 TGA protein molecular weights: 8987.08

6.LP4947

A: nucleotide sequence (SEQ ID NO:16) length: 2471 bases

B: aminoacid sequence (SEQ ID NO:18) length: 146 amino acid

C. Nucleotide and amino acid composite sequence (SEQ ID NO:17) clone number and protein name: LP4947 start code: 108 ATG stop coding: 546 TGA protein molecular weights: 16017.98

7.LP5553

A: nucleotide sequence (SEQ ID NO:19) length: 1934 bases

B: aminoacid sequence (SEQ ID NO:21) length: 96 amino acid

C. Nucleotide and amino acid composite sequence (SEQ ID NO:20) clone number and protein name: LP5553 start code: 837 ATG stop coding: 1125 TAG protein molecular weights: 10235.89

8.LP6347

A: nucleotide sequence (SEQ ID NO:22) length: 1915 bases

B: aminoacid sequence (SEQ ID NO:24) length: 91 amino acid

C. Nucleotide and amino acid composite sequence (SEQ ID NO:23) clone number and protein name: LP6347 start code: 343 ATG stop coding: 616 TGA protein molecular weights: 9540.07

9.LP8067

A: nucleotide sequence (SEQ ID NO:25) length: 1575 bases

B: aminoacid sequence (SEQ ID NO:27) length: 200 amino acid

C. Nucleotide and amino acid composite sequence (SEQ ID NO:26) clone number and protein name: LP8067 start code: 754 ATG stop coding: 1354 TGA protein molecular weights: 20839.38

10.LP8151

A: nucleotide sequence (SEQ ID NO:28) length: 1800 bases

B: aminoacid sequence (SEQ ID NO:30) length: 168 amino acid

C. Nucleotide and amino acid composite sequence (SEQ ID NO:29) clone number and protein name: LP8151 start code: 409 ATG stop coding: 913 TGA protein molecular weights: 18356.29

All quote in this application as a reference at all documents that the present invention mentions, just quoted as a reference separately as each piece document.Should be understood that in addition those skilled in the art can make various changes or modifications the present invention after having read above-mentioned teachings of the present invention, these equivalent form of values fall within the application's appended claims institute restricted portion equally.

Sequence table

＜110〉Shanghai Xinshijie Gene Techn Development Co., Ltd.

＜120〉have new people's albumen and the encoding sequence thereof that promotes mouse NIII/3T3 cell transformation function

<130>025304

<160>50

<170>PatentIn version 3.1

<210>1

<211>2032

<212>DNA

＜213〉homo sapiens (Homo sapiens)

<400>1

gctgagttaa tgttgagcca ctccatgtga cacagaagcc tcttgtcact gtgttgttca 60

ttggggtgcc gaggccagct catggtatct cctgagagcc agtcgttcac tttccagtat 120

ttttttttgc gggggcgtgg ggggacggat gttcactctt gttgcccagg ctggaacaca 180

atggcacgat ctcggttcac cacgacctcc acctcctgag gcaggagagt cgcttgaacc 240

caggaggcgg aggtcgtggt aagccaagat cacgccattg cactccagcc tggcaacaag 300

gagcaaaact ccgtctgaaa aaaaaaaaaa aaattagcca ggcctggtgg tgcacgcttg 360

taatcccagc tacttgagag gctgaggcag gagaattgct tgaacccagg aggtggaggt 420

tgcagtgagc cgagatcgtg ccactgccct ccagtctggg tgacagagtg agattacatc 480

tcaaaaaaaa aaaaagggtg ggaggaataa gttttacacc ctcctcccca ccccacatgg 540

aaatcatcct taaccactag agcggtgttg tcctgaagcg ctctctgtgg tgacggatgg 600

ttttccacct gcactgagtt ggttgtcagc agccacacgt gccttccgcg cacttgaaac 660

atggctaatg tgactggcta cctgagtctt tatttttctt taacgtacac gtggacagct 720

cagcgtgggt agtgaggcgc ggcctgagcc ccctgtggct ctgcacgcca gcctctgccg 780

tgttatgatc agctgcaaag ttggtaacca tgccatagta gtggaggctt tggggagggg 840

agagtaaggt ggtttgtagg actagatgga ccagataatg catacccggt aaaataaatg 900

cttgtgtggt ttgcagaatc gtcagtagtg gggcgacaga gaccagggtg gcgctttcca 960

gtggggtcac tggtcctgag cccccatggc atagaggtac cgcggccggc tgtgtccgca 1020

tctgctggcc tctattctcc ctgtgttatt tacaaagatg tttgtctcct agcaggtgcg 1080

ccacgtgagg cccagagccg cactcgctca ccctgtgcgc tctcccccaa ccgccccgca 1140

ccgtccccgt ccctggcacg gcgcttcgtg ccttccacag gcttcataac tgctttgttt 1200

ctaaagtccc gttctgacaa cgccatcgag agccacctgt ctctgattta gatcctaact 1260

caggaaggac ccatttcccc agcagctgca gcctctgttg atgtaatgag cacggtatgg 1320

tatggagaca gtaactcctt actgcagccc tgcgagggct cctgtcccca cttgaccctc 1380

gtagcaaccc cctgaggtcg caacagtctt tgtcttatcc actgctcttg ggagggtctg 1440

tggctcttgg ttgagcgtct tcaccgcacc ctcatcctgg tgatgccgcg atgctccaac 1500

cccagagcgg acacttggcg tcggaattgc agggagtccc tccgctgtag aaagggctcc 1560

tcctcttcct tcccccatgc catcccagga gaaaggcctg ccgtggagtg ccgcttcctt 1620

tgtctccaga cagtccagcc tgggcgacag agcaggactc tttctttgtc tcaaaaaaaa 1680

aaaaaagtac atgtttagcc aggcatggtg gctcatgcct gtaatcccag cactttggga 1740

ggccgaggca ggtggatcaa aaggtcaaga gatggagacc atctggccaa catggtgaaa 1800

ccccatctct actaaaaata aaaaaatcag ctgggcgtgg tggtgcacgc ctgtagtccc 1860

atctacttgg gagactgagg caggagaatc tcttgaaccg gggaggcaga ggttgcagtg 1920

agccgagatt gcgccactgc actccagcct ggcaacagag agagactcca tctctaaaaa 1980

aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa aa 2032

<210>2

<211>2032

<212>DNA

＜213〉homo sapiens (Homo sapiens)

<220>

<221>CDS

<222>(898)..(1248)

<223>

<400>2

gctgagttaa tgttgagcca ctccatgtga cacagaagcc tcttgtcact gtgttgttca 60

ttggggtgcc gaggccagct catggtatct cctgagagcc agtcgttcac tttccagtat 120

ttttttttgc gggggcgtgg ggggacggat gttcactctt gttgcccagg ctggaacaca 180

atggcacgat ctcggttcac cacgacctcc acctcctgag gcaggagagt cgcttgaacc 240

caggaggcgg aggtcgtggt aagccaagat cacgccattg cactccagcc tggcaacaag 300

gagcaaaact ccgtctgaaa aaaaaaaaaa aaattagcca ggcctggtgg tgcacgcttg 360

taatcccagc tacttgagag gctgaggcag gagaattgct tgaacccagg aggtggaggt 420

tgcagtgagc cgagatcgtg ccactgccct ccagtctggg tgacagagtg agattacatc 480

tcaaaaaaaa aaaaagggtg ggaggaataa gttttacacc ctcctcccca ccccacatgg 540

aaatcatcct taaccactag agcggtgttg tcctgaagcg ctctctgtgg tgacggatgg 600

ttttccacct gcactgagtt ggttgtcagc agccacacgt gccttccgcg cacttgaaac 660

atggctaatg tgactggcta cctgagtctt tatttttctt taacgtacac gtggacagct 720

cagcgtgggt agtgaggcgc ggcctgagcc ccctgtggct ctgcacgcca gcctctgccg 780

tgttatgatc agctgcaaag ttggtaacca tgccatagta gtggaggctt tggggagggg 840

agagtaaggt ggtttgtagg actagatgga ccagataatg catacccggt aaaataa 897

atg ctt gtg tgg ttt gca gaa tcg tca gta gtg ggg cga cag aga cca 945

Met Leu Val Trp Phe Ala Glu Ser Ser Val Val Gly Arg Gln Arg Pro

1 5 10 15

ggg tgg cgc ttt cca gtg ggg tca ctg gtc ctg agc ccc cat ggc ata 993

Gly Trp Arg Phe Pro Val Gly Ser Leu Val Leu Ser Pro His Gly Ile

20 25 30

gag gta ccg cgg ccg gct gtg tcc gca tct gct ggc ctc tat tct ccc 1041

Glu Val Pro Arg Pro Ala Val Ser Ala Ser Ala Gly Leu Tyr Ser Pro

35 40 45

tgt gtt att tac aaa gat gtt tgt ctc cta gca ggt gcg cca cgt gag 1089

Cys Val Ile Tyr Lys Asp Val Cys Leu Leu Ala Gly Ala Pro Arg Glu

50 55 60

gcc cag agc cgc act cgc tca ccc tgt gcg ctc tcc ccc aac cgc ccc 1137

Ala Gln Ser Arg Thr Arg Ser Pro Cys Ala Leu Ser Pro Asn Arg Pro

65 70 75 80

gca ccg tcc ccg tcc ctg gca cgg cgc ttc gtg cct tcc aca ggc ttc 1185

Ala Pro Ser Pro Ser Leu Ala Arg Arg Phe Val Pro Ser Thr Gly Phe

85 90 95

ata act gct ttg ttt cta aag tcc cgt tct gac aac gcc atc gag agc 1233

Ile Thr Ala Leu Phe Leu Lys Ser Arg Ser Asp Asn Ala Ile Glu Ser

100 105 110

cac ctg tct ctg att tagatcctaa ctcaggaagg acccatttcc ccagcagctg 1288

His Leu Ser Leu Ile

115

cagcctctgt tgatgtaatg agcacggtat ggtatggaga cagtaactcc ttactgcagc 1348

cctgcgaggg ctcctgtccc cacttgaccc tcgtagcaac cccctgaggt cgcaacagtc 1408

tttgtcttat ccactgctct tgggagggtc tgtggctctt ggttgagcgt cttcaccgca 1468

ccctcatcct ggtgatgccg cgatgctcca accccagagc ggacacttgg cgtcggaatt 1528

gcagggagtc cctccgctgt agaaagggct cctcctcttc cttcccccat gccatcccag 1588

gagaaaggcc tgccgtggag tgccgcttcc tttgtctcca gacagtccag cctgggcgac 1648

agagcaggac tctttctttg tctcaaaaaa aaaaaaaagt acatgtttag ccaggcatgg 1708

tggctcatgc ctgtaatccc agcactttgg gaggccgagg caggtggatc aaaaggtcaa 1768

gagatggaga ccatctggcc aacatggtga aaccccatct ctactaaaaa taaaaaaatc 1828

agctgggcgt ggtggtgcac gcctgtagtc ccatctactt gggagactga ggcaggagaa 1888

tctcttgaac cggggaggca gaggttgcag tgagccgaga ttgcgccact gcactccagc 1948

ctggcaacag agagagactc catctctaaa aaaaaaaaaa aaaaaaaaaa aaaaaaaaaa 2008

aaaaaaaaaa aaaaaaaaaa aaaa 2032

<210>3

<211>117

<212>PRT

＜213〉homo sapiens (Homo sapiens)

<400>3

Met Leu Val Trp Phe Ala Glu Ser Ser Val Val Gly Arg Gln Arg Pro

1 5 10 15

Gly Trp Arg Phe Pro Val Gly Ser Leu Val Leu Ser Pro His Gly Ile

20 25 30

Glu Val Pro Arg Pro Ala Val Ser Ala Ser Ala Gly Leu Tyr Ser Pro

35 40 45

Cys Val Ile Tyr Lys Asp Val Cys Leu Leu Ala Gly Ala Pro Arg Glu

50 55 60

Ala Gln Ser Arg Thr Arg Ser Pro Cys Ala Leu Ser Pro Asn Arg Pro

65 70 75 80

Ala Pro Ser Pro Ser Leu Ala Arg Arg Phe Val Pro Ser Thr Gly Phe

85 90 95

Ile Thr Ala Leu Phe Leu Lys Ser Arg Ser Asp Asn Ala Ile Glu Ser

100 105 110

His Leu Ser Leu Ile

115

<210>4

<211>926

<212>DNA

＜213〉homo sapiens (Homo sapiens)

<400>4

gcccttctac ccatatctat tgagtgcttg ttatgaagaa agagagcagc acaccggccc 60

tctgtctgct gggggagact gacgagtgaa cagattattc cagaaacctg gggtaagcaa 120

gatagtggat aggggacaga gggccaaagc ttcctagact gatgattagc tgagctgagt 180

gataaaagag aagtcagata attacacaaa aatgagagcg gcagcccagc ccatgcaaaa 240

gcatggccct gaccggaagc taccaggaag gattctgatg tgcctggcct gggtggtgcc 300

tgctcccaga gcctgcaagc tgggttctgg ggaagcatcc tctaggtgat agagcaggct 360

gtagagcaag ccctgttctg agtgaggagg acaggccctg tgtgtgatgg ccccacctga 420

gccactggca tgggcagtca gttcccaaga cggagtccag gacagacaaa aaatgaacag 480

ctgaaaagtg caagtagtgt aggttcaagg aagtggtgta ggaagaggga gacggaatgg 540

gatctgagga gggctgcaca gcacacagta ggcggcacaa aagtctgctc agttaggtca 600

catgctccag aggcactcac tgcaaaagag cctgaagatt gaactgaaat atgccatcgg 660

ctttgctgag tatgaatgcc aagaggagca gagagaagtc aagccctcta ggtgataggc 720

aggaacgagc tgaaagaagg acataaatct tggtttgctc agacgggcct ggattatact 780

tacgttaatt atgtttagtg cccttttcat gctaagaagt gtcctacttt ggatgataaa 840

ttgtacagtc actctaggtt taagtgatac tcaggcagtc tggcttggaa agtcaagtca 900

ggagaagaaa aaaaaaaaaa aaaaaa 926

<210>5

<211>926

<212>DNA

＜213〉homo sapiens (Homo sapiens)

<220>

<221>CDS

<222>(430)..(639)

<223>

<400>5

gcccttctac ccatatctat tgagtgcttg ttatgaagaa agagagcagc acaccggccc 60

tctgtctgct gggggagact gacgagtgaa cagattattc cagaaacctg gggtaagcaa 120

gatagtggat aggggacaga gggccaaagc ttcctagact gatgattagc tgagctgagt 180

gataaaagag aagtcagata attacacaaa aatgagagcg gcagcccagc ccatgcaaaa 240

gcatggccct gaccggaagc taccaggaag gattctgatg tgcctggcct gggtggtgcc 300

tgctcccaga gcctgcaagc tgggttctgg ggaagcatcc tctaggtgat agagcaggct 360

gtagagcaag ccctgttctg agtgaggagg acaggccctg tgtgtgatgg ccccacctga 420

gccactggc atg ggc agt cag ttc cca aga cgg agt cca gga cag aca aaa 471

Met Gly Ser Gln Phe Pro Arg Arg Ser Pro Gly Gln Thr Lys

1 5 10

aat gaa cag ctg aaa agt gca agt agt gta ggt tca agg aag tgg tgt 519

Asn Glu Gln Leu Lys Ser Ala Ser Ser Val Gly Ser Arg Lys Trp Cys

15 20 25 30

agg aag agg gag acg gaa tgg gat ctg agg agg gct gca cag cac aca 567

Arg Lys Arg Glu Thr Glu Trp Asp Leu Arg Arg Ala Ala Gln His Thr

35 40 45

gta ggc ggc aca aaa gtc tgc tca gtt agg tca cat gct cca gag gca 615

Val Gly Gly Thr Lys Val Cys Ser Val Arg Ser His Ala Pro Glu Ala

50 55 60

ctc act gca aaa gag cct gaa gat tgaactgaaa tatgccatcg gctttgctga 669

Leu Thr Ala Lys Glu Pro Glu Asp

65 70

gtatgaatgc caagaggagc agagagaagt caagccctct aggtgatagg caggaacgag 729

ctgaaagaag gacataaatc ttggtttgct cagacgggcc tggattatac ttacgttaat 789

tatgtttagt gcccttttca tgctaagaag tgtcctactt tggatgataa attgtacagt 849

cactctaggt ttaagtgata ctcaggcagt ctggcttgga aagtcaagtc aggagaagaa 909

aaaaaaaaaa aaaaaaa 926

<210>6

<211>70

<212>PRT

＜213〉homo sapiens (Homo sapiens)

<400>6

Met Gly Ser Gln Phe Pro Arg Arg Ser Pro Gly Gln Thr Lys Asn Glu

1 5 10 15

Gln Leu Lys Ser Ala Ser Ser Val Gly Ser Arg Lys Trp Cys Arg Lys

20 25 30

Arg Glu Thr Glu Trp Asp Leu Arg Arg Ala Ala Gln His Thr Val Gly

35 40 45

Gly Thr Lys Val Cys Ser Val Arg Ser His Ala Pro Glu Ala Leu Thr

50 55 60

Ala Lys Glu Pro Glu Asp

65 70

<210>7

<211>1814

<212>DNA

＜213〉homo sapiens (Homo sapiens)

<400>7

ggttttgtga actgtacaat gtacaaatat gagatgatgc tgccaagtta ttcaaagggt 60

cattcatcag tgaatcaacg tatcaacaag cctattagct ggacagttga ggatacacca 120

ataagccgtc tagctgggga tgagaagagg gagggctgca cgtgaagggt taattcacaa 180

tgtagagtga tagtggtgag cagactttta ggctgaaggc tgaagggctc atccttttta 240

aattttgaaa caaggtcctg cattgtcacc cagtcaccca ggctgagtac agtggcacaa 300

tcgtggctca ttgtagtctc cacctcccag gctcaagcaa tcctcccatc tcagcctccc 360

agctactcgg aaggctgagg caggagaatc gcttgaactc gggaggtgga ggttgtagtg 420

agctgaggtc atgccactgc actccagcct ggtgacagaa cgagactctg tctcataaat 480

aaataaataa ataaataaat aaataaatag tcaggcatgg tggcatgcac ctgtagtggg 540

aggctgacat caggggatca cttgagctta gaaggtggag gctgcagtga gctctgactg 600

caccactgca ctccagcctg gggaacagag tgagaccctg tctcaaaaac aaaaaaacaa 660

aaaacaaaaa caaggttaag actgtcttgg aaactgaagg ggcccagaaa acctacaaga 720

cctgcctgag attttattta gggataagaa gaaagcaagc aagctgaaaa ggacagaaaa 780

agaaaataat gttgacttca gtttgcaggt taaatcccat tgaccatata agggttacat 840

ccatgtaaag tgcctggctc atagtagtgc acccatcatt tccccttcac cataggagaa 900

gctgcatccc aggcgatcca agcccaacga attcctccca ctcccaggaa gggcttgctt 960

gaggccagag gctggcaggg aaaaaaaact cctctgcaaa atgttgcctc agcctctgga 1020

atttacactt accccactgc cgtctgctca acattcctgc ctgaaattcc agccgaacca 1080

taggaaacaa ctgctctgtg aaggtccagg aactggcagg ggctggcagg cctctcccaa 1140

ctcccaaatt gctgtcacag gctatgacct cacttcctta gcccgctcca gggtgagcct 1200

cctctccagt cctgaatgtt cggtgggcag gagggcaaca gcgtgggcct ggaccagatc 1260

atggcaggcc actgagcagg gcttggccag gttactgccg tggatcattt cccattttgg 1320

agagtcaaac cccaataccc ttgctcaaag ttaaatgcac agaggaaatt ccctgttctg 1380

ggaggcttgg gggaagtgga tgctccctcg gctcagcttt cttgatgagt cgaagggagg 1440

aaaggagttg tgtttcttga gtgcttactc tataccaggc cctgtgctag gcttacactc 1500

ttcagaatga ctgtgtgagg ccagatgcag tgactcacgc ctgtaatccc aaaatgctgg 1560

gattacagga gtgagccgct gtgcttggcc aagagggata tttttaaccc gagaacggtc 1620

atgaagcact tcctggagaa ggtgaaatag cactggtcct tgaaagacat ttagaattct 1680

gaccagtcaa taagatgaaa gatactgtag gggtatctgt aggaatggcc tacgtagaag 1740

tgaggagaga gaaaacctaa cagtggtggg tggtttgtgt tgggaagcaa aaaacgaaaa 1800

aaaaaaaaaa aaaa 1814

<210>8

<211>1814

<212>DNA

＜213〉homo sapiens (Homo sapiens)

<220>

<221>CDS

<222>(1001)..(1351)

<223>

<400>8

ggttttgtga actgtacaat gtacaaatat gagatgatgc tgccaagtta ttcaaagggt 60

cattcatcag tgaatcaacg tatcaacaag cctattagct ggacagttga ggatacacca 120

ataagccgtc tagctgggga tgagaagagg gagggctgca cgtgaagggt taattcacaa 180

tgtagagtga tagtggtgag cagactttta ggctgaaggc tgaagggctc atccttttta 240

aattttgaaa caaggtcctg cattgtcacc cagtcaccca ggctgagtac agtggcacaa 300

tcgtggctca ttgtagtctc cacctcccag gctcaagcaa tcctcccatc tcagcctccc 360

agctactcgg aaggctgagg caggagaatc gcttgaactc gggaggtgga ggttgtagtg 420

agctgaggtc atgccactgc actccagcct ggtgacagaa cgagactctg tctcataaat 480

aaataaataa ataaataaat aaataaatag tcaggcatgg tggcatgcac ctgtagtggg 540

aggctgacat caggggatca cttgagctta gaaggtggag gctgcagtga gctctgactg 600

caccactgca ctccagcctg gggaacagag tgagaccctg tctcaaaaac aaaaaaacaa 660

aaaacaaaaa caaggttaag actgtcttgg aaactgaagg ggcccagaaa acctacaaga 720

cctgcctgag attttattta gggataagaa gaaagcaagc aagctgaaaa ggacagaaaa 780

agaaaataat gttgacttca gtttgcaggt taaatcccat tgaccatata agggttacat 840

ccatgtaaag tgcctggctc atagtagtgc acccatcatt tccccttcac cataggagaa 900

gctgcatccc aggcgatcca agcccaacga attcctccca ctcccaggaa gggcttgctt 960

gaggccagag gctggcaggg aaaaaaaact cctctgcaaa atg ttg cct cag cct 1015

Met Leu Pro Gln Pro

1 5

ctg gaa ttt aca ctt acc cca ctg ccg tct gct caa cat tcc tgc ctg 1063

Leu Glu Phe Thr Leu Thr Pro Leu Pro Ser Ala Gln His Ser Cys Leu

10 15 20

aaa ttc cag ccg aac cat agg aaa caa ctg ctc tgt gaa ggt cca gga 1111

Lys Phe Gln Pro Asn His Arg Lys Gln Leu Leu Cys Glu Gly Pro Gly

25 30 35

act ggc agg ggc tgg cag gcc tct ccc aac tcc caa att gct gtc aca 1159

Thr Gly Arg Gly Trp Gln Ala Ser Pro Asn Ser Gln Ile Ala Val Thr

40 45 50

ggc tat gac ctc act tcc tta gcc cgc tcc agg gtg agc ctc ctc tcc 1207

Gly Tyr Asp Leu Thr Ser Leu Ala Arg Ser Arg Val Ser Leu Leu Ser

55 60 65

agt cct gaa tgt tcg gtg ggc agg agg gca aca gcg tgg gcc tgg acc 1255

Ser Pro Glu Cys Ser Val Gly Arg Arg Ala Thr Ala Trp Ala Trp Thr

70 75 80 85

aga tca tgg cag gcc act gag cag ggc ttg gcc agg tta ctg ccg tgg 1303

Arg Ser Trp Gln Ala Thr Glu Gln Gly Leu Ala Arg Leu Leu Pro Trp

90 95 100

atc att tcc cat ttt gga gag tca aac ccc aat acc ctt gct caa agt 1351

Ile Ile Ser His Phe Gly Glu Ser Asn Pro Asn Thr Leu Ala Gln Ser

105 110 115

taaatgcaca gaggaaattc cctgttctgg gaggcttggg ggaagtggat gctccctcgg 1411

ctcagctttc ttgatgagtc gaagggagga aaggagttgt gtttcttgag tgcttactct 1471

ataccaggcc ctgtgctagg cttacactct tcagaatgac tgtgtgaggc cagatgcagt 1531

gactcacgcc tgtaatccca aaatgctggg attacaggag tgagccgctg tgcttggcca 1591

agagggatat ttttaacccg agaacggtca tgaagcactt cctggagaag gtgaaatagc 1651

actggtcctt gaaagacatt tagaattctg accagtcaat aagatgaaag atactgtagg 1711

ggtatctgta ggaatggcct acgtagaagt gaggagagag aaaacctaac agtggtgggt 1771

ggtttgtgtt gggaagcaaa aaacgaaaaa aaaaaaaaaa aaa 1814

<210>9

<211>117

<212>PRT

＜213〉homo sapiens (Homo sapiens)

<400>9

Met Leu Pro Gln Pro Leu Glu Phe Thr Leu Thr Pro Leu Pro Ser Ala

1 5 10 15

Gln His Ser Cys Leu Lys Phe Gln Pro Asn His Arg Lys Gln Leu Leu

20 25 30

Cys Glu Gly Pro Gly Thr Gly Arg Gly Trp Gln Ala Ser Pro Asn Ser

35 40 45

Gln Ile Ala Val Thr Gly Tyr Asp Leu Thr Ser Leu Ala Arg Ser Arg

50 55 60

Val Ser Leu Leu Ser Ser Pro Glu Cys Ser Val Gly Arg Arg Ala Thr

65 70 75 80

Ala Trp Ala Trp Thr Arg Ser Trp Gln Ala Thr Glu Gln Gly Leu Ala

85 90 95

Arg Leu Leu Pro Trp Ile Ile Ser His Phe Gly Glu Ser Asn Pro Asn

100 105 110

Thr Leu Ala Gln Ser

115

<210>10

<211>1199

<212>DNA

＜213〉homo sapiens (Homo sapiens)

<400>10

gaagactcag tcttctctgt tgttggttga ccaataaata aatatttagc ctttttctgg 60

agggagatca caaaacagga cagagctctt cctgaatcct tcaggcggat tcgccctctc 120

ttcctgttct gcggaggaca gtcctggggc ctttgctgtg tcaaccacgc cccgaggcac 180

cccagaagct gcatctgtcg agtctgtgct gtaatcatgg ccttgaaggt ggaaggcagg 240

tctgagatgg gaggtgacag gagcaggtct gggccggagc aaccgcaagc gcccgtctcc 300

ttctctccct ccctccctcc ctccttccct cctccctccc tccatcaaac caggcagagc 360

tggggtctgg ggcaccccag ggagacagac ctgccacctc agcaatggct tccaggtggg 420

aatgggggtc ttttagtcca gacttttcca gagatgctgg aaacacagct tgtcctgctg 480

tttaaatgtt cgcaattatt aatttttgca atgctttgta aaaactaaag gtacaatagt 540

tgggttccac cctgggaccg ccagtttgca atccttctct tagggactga gtcaggctgg 600

cggggggcgg gctgcagggc tcccacttga accagaagtc cctgtcctag atgtctagct 660

ccaaatgtgt tccctgccct ttcctgcttc cctgtagttc ctgcccgcac ccaggatccc 720

cagccatctg cccaagcctc cccaccccca ccacgccgcc cccactcccc acatgatggg 780

gaagctggcc aagacattca ttcctccaca ccccctgccc ccatcagcag ctccaccctc 840

agcaccccca cctcagctcc tcctgcaagg cctccgtgga tggggggtgg cggtggagaa 900

agcctttctt ttataattgt tttaaaccta cttttatttt tatttttgta gagacaagat 960

ctctctatgt tgcccaggct ggtcttgaac tcctggactc aaaggatcct ccagcctcgg 1020

ccccccagag tgctgggatt acaggcgtga gccatggtgc ccagcctggt aattaacaga 1080

tacttcgtga ccacccacta tgcaccaggc cctgttctat aattcagatg aaaatccctg 1140

agaggagctg acgtgctagc aggggaggca gatagcacca caaaaaaaaa aaaaaaaaa 1199

<210>11

<211>1199

<212>DNA

＜213〉homo sapiens (Homo sapiens)

<220>

<221>CDS

<222>(217)..(525)

<223>

<400>11

gaagactcag tcttctctgt tgttggttga ccaataaata aatatttagc ctttttctgg 60

agggagatca caaaacagga cagagctctt cctgaatcct tcaggcggat tcgccctctc 120

ttcctgttct gcggaggaca gtcctggggc ctttgctgtg tcaaccacgc cccgaggcac 180

cccagaagct gcatctgtcg agtctgtgct gtaatc atg gcc ttg aag gtg gaa 234

Met Ala Leu Lys Val Glu

1 5

ggc agg tct gag atg gga ggt gac agg agc agg tct ggg ccg gag caa 282

Gly Arg Ser Glu Met Gly Gly Asp Arg Ser Arg Ser Gly Pro Glu Gln

10 15 20

ccg caa gcg ccc gtc tcc ttc tct ccc tcc ctc cct ccc tcc ttc cct 330

Pro Gln Ala Pro Val Ser Phe Ser Pro Ser Leu Pro Pro Ser Phe Pro

25 30 35

cct ccc tcc ctc cat caa acc agg cag agc tgg ggt ctg ggg cac ccc 378

Pro Pro Ser Leu His Gln Thr Arg Gln Ser Trp Gly Leu Gly His Pro

40 45 50

agg gag aca gac ctg cca cct cag caa tgg ctt cca ggt ggg aat ggg 426

Arg Glu Thr Asp Leu Pro Pro Gln Gln Trp Leu Pro Gly Gly Asn Gly

55 60 65 70

ggt ctt tta gtc cag act ttt cca gag atg ctg gaa aca cag ctt gtc 474

Gly Leu Leu Val Gln Thr Phe Pro Glu Met Leu Glu Thr Gln Leu Val

75 80 85

ctg ctg ttt aaa tgt tcg caa tta tta att ttt gca atg ctt tgt aaa 522

Leu Leu Phe Lys Cys Ser Gln Leu Leu Ile Phe Ala Met Leu Cys Lys

90 95 100

aac taaaggtaca atagttgggt tccaccctgg gaccgccagt ttgcaatcct 575

Asn

tctcttaggg actgagtcag gctggcgggg ggcgggctgc agggctccca cttgaaccag 635

aagtccctgt cctagatgtc tagctccaaa tgtgttccct gccctttcct gcttccctgt 695

agttcctgcc cgcacccagg atccccagcc atctgcccaa gcctccccac ccccaccacg 755

ccgcccccac tccccacatg atggggaagc tggccaagac attcattcct ccacaccccc 815

tgcccccatc agcagctcca ccctcagcac ccccacctca gctcctcctg caaggcctcc 875

gtggatgggg ggtggcggtg gagaaagcct ttcttttata attgttttaa acctactttt 935

atttttattt ttgtagagac aagatctctc tatgttgccc aggctggtct tgaactcctg 995

gactcaaagg atcctccagc ctcggccccc cagagtgctg ggattacagg cgtgagccat 1055

ggtgcccagc ctggtaatta acagatactt cgtgaccacc cactatgcac caggccctgt 1115

tctataattc agatgaaaat ccctgagagg agctgacgtg ctagcagggg aggcagatag 1175

caccacaaaa aaaaaaaaaa aaaa 1199

<210>12

<211>103

<212>PRT

＜213〉homo sapiens (Homo sapiens)

<400>12

Met Ala Leu Lys Val Glu Gly Arg Ser Glu Met Gly Gly Asp Arg Ser

1 5 10 15

Arg Ser Gly Pro Glu Gln Pro Gln Ala Pro Val Ser Phe Ser Pro Ser

20 25 30

Leu Pro Pro Ser Phe Pro Pro Pro Ser Leu His Gln Thr Arg Gln Ser

35 40 45

Trp Gly Leu Gly His Pro Arg Glu Thr Asp Leu Pro Pro Gln Gln Trp

50 55 60

Leu Pro Gly Gly Asn Gly Gly Leu Leu Val Gln Thr Phe Pro Glu Met

65 70 75 80

Leu Glu Thr Gln Leu Val Leu Leu Phe Lys Cys Ser Gln Leu Leu Ile

85 90 95

Phe Ala Met Leu Cys Lys Asn

100

<210>13

<211>1269

<212>DNA

＜213〉homo sapiens (Homo sapiens)

<400>13

gctgagatgt ggggagcgcc tctccccgcc gccccgtctg ggatgtgagg agtgcctcta 60

cccggccgcc ccgtctgaga agtgaggaga ccctccgcct ggcaaccgcc ccgtctgaga 120

agtgaggagc ccctccaccc ggcagccacc ccgtctggga agtgaggagc gtctccgcca 180

gcagccaccc cgtccgggag ggaggtgggg ggggtcagcc cgcccggcca gccgccccgt 240

ccaggaggga ggtggggggg tcagccccgc ccggccagcc gccccgtccg ggagggaggt 300

gggggggtca gccccctgcc cggccagccg ccccgtcggg gaggtgaggg gcgcctttgc 360

ctggccgccc ctactgggaa gtgaggagcc cctctgcccg gccagccacc ccgtccggga 420

gggaggtggg ggggtcagcc ccccgccagg ccagccaccc cgtccgggag ggaggtgggg 480

gtgtcagccc cccgcccggc cagccgccct gtccgggagg tgaggggcgc ctctgcccgg 540

ccgcccctac tgggaagtga ggagcccctc tgcccggcca gccgccccgt ccgggaggga 600

ggtggggggg tcagccccca gcccggccag tcgccccgtc ggggaggtga ggggcgcctc 660

tgcccggctg cccctactgg gaagtgagga gcccctctgc ccagccgcca ccccgtctgg 720

gaggtgtgcc cagcagctca ttgagaacgg gccatgatga caatggcggt tttgtggaat 780

agaaaggggg gaaagttggg ggaaaagatt gagaggttgg atggttgccg tgtctgtgta 840

gaaagacgta gacatgggag acttctcatt ttgttctgta ctaagaaaaa ttattctgcc 900

ttgggatcct gttgatctgt gaccttaccc ccaaccctgt gctctctgaa acatgtgctg 960

tgtccaccca gggttaaatg gatgaagggc ggtgcaagat gtgctttgtt aaacagatgc 1020

ttgaaggcag catgctcgtt aaaagtcatc accactccct aatctcaagt accccgggac 1080

acaaacactg cggaaggccg cagggtcctc tgcctaggaa aaccagagac ctttgttcac 1140

ttgtttatct gctgaccttc cctccactat tgtcctatga ccctgccaaa tccccccctg 1200

cgagaaacac ccaagaatga tcaataaaaa taaaaaataa aaaaaataaa aaaaaaaaaa 1260

aaaaaaaaa 1269

<210>14

<211>1269

<212>DNA

＜213〉homo sapiens (Homo sapiens)

<220>

<221>CDS

<222>(978)..(1217)

<223>

<400>14

gctgagatgt ggggagcgcc tctccccgcc gccccgtctg ggatgtgagg agtgcctcta 60

cccggccgcc ccgtctgaga agtgaggaga ccctccgcct ggcaaccgcc ccgtctgaga 120

agtgaggagc ccctccaccc ggcagccacc ccgtctggga agtgaggagc gtctccgcca 180

gcagccaccc cgtccgggag ggaggtgggg ggggtcagcc cgcccggcca gccgccccgt 240

ccaggaggga ggtggggggg tcagccccgc ccggccagcc gccccgtccg ggagggaggt 300

gggggggtca gccccctgcc cggccagccg ccccgtcggg gaggtgaggg gcgcctttgc 360

ctggccgccc ctactgggaa gtgaggagcc cctctgcccg gccagccacc ccgtccggga 420

gggaggtggg ggggtcagcc ccccgccagg ccagccaccc cgtccgggag ggaggtgggg 480

gtgtcagccc cccgcccggc cagccgccct gtccgggagg tgaggggcgc ctctgcccgg 540

ccgcccctac tgggaagtga ggagcccctc tgcccggcca gccgccccgt ccgggaggga 600

ggtggggggg tcagccccca gcccggccag tcgccccgtc ggggaggtga ggggcgcctc 660

tgcccggctg cccctactgg gaagtgagga gcccctctgc ccagccgcca ccccgtctgg 720

gaggtgtgcc cagcagctca ttgagaacgg gccatgatga caatggcggt tttgtggaat 780

agaaaggggg gaaagttggg ggaaaagatt gagaggttgg atggttgccg tgtctgtgta 840

gaaagacgta gacatgggag acttctcatt ttgttctgta ctaagaaaaa ttattctgcc 900

ttgggatcct gttgatctgt gaccttaccc ccaaccctgt gctctctgaa acatgtgctg 960

tgtccaccca gggttaa atg gat gaa ggg cgg tgc aag atg tgc ttt gtt 1010

Met Asp Glu Gly Arg Cys Lys Met Cys Phe Val

1 5 10

aaa cag atg ctt gaa ggc agc atg ctc gtt aaa agt cat cac cac tcc 1058

Lys Gln Met Leu Glu Gly Ser Met Leu Val Lys Ser His His His Ser

15 20 25

cta atc tca agt acc ccg gga cac aaa cac tgc gga agg ccg cag ggt 1106

Leu Ile Ser Ser Thr Pro Gly His Lys His Cys Gly Arg Pro Gln Gly

30 35 40

cct ctg cct agg aaa acc aga gac ctt tgt tca ctt gtt tat ctg ctg 1154

Pro Leu Pro Arg Lys Thr Arg Asp Leu Cys Ser Leu Val Tyr Leu Leu

45 50 55

acc ttc cct cca cta ttg tcc tat gac cct gcc aaa tcc ccc cct gcg 1202

Thr Phe Pro Pro Leu Leu Ser Tyr Asp Pro Ala Lys Ser Pro Pro Ala

60 65 70 75

aga aac acc caa gaa tgatcaataa aaataaaaaa taaaaaaaat aaaaaaaaaa 1257

Arg Asn Thr Gln Glu

80

aaaaaaaaaa aa 1269

<210>15

<211>80

<212>PRT

＜213〉homo sapiens (Homo sapiens)

<400>15

Met Asp Glu Gly Arg Cys Lys Met Cys Phe Val Lys Gln Met Leu Glu

1 5 10 15

Gly Ser Met Leu Val Lys Ser His His His Ser Leu Ile Ser Ser Thr

20 25 30

Pro Gly His Lys His Cys Gly Arg Pro Gln Gly Pro Leu Pro Arg Lys

35 40 45

Thr Arg Asp Leu Cys Ser Leu Val Tyr Leu Leu Thr Phe Pro Pro Leu

50 55 60

Leu Ser Tyr Asp Pro Ala Lys Ser Pro Pro Ala Arg Asn Thr Gln Glu

65 70 75 80

<210>16

<211>2471

<212>DNA

＜213〉homo sapiens (Homo sapiens)

<400>16

gttcgtttag aacagaaact gttcatactt ggtgcgctgt ggactcttgt gataattaac 60

caagagtagc tctatttgtc caacctcaca cctaaagaag aaagaaaatg gcttgtgctg 120

agttttcttt tcatgtacca agtcttgaag agcttgctgg agttatgcag aaggggttaa 180

aagataactt tgctgatgtc caggtctctg tagttgattg ccctgatttg actaaggaac 240

cctttacctt tcctgtaaaa ggcatctgtg ggaaaactag aattgcagaa gttggaggtg 300

tgccttactt attgcctctt gtaaaccaaa aaaaagttta tgatctgaat aaaattgcaa 360

aagaaatcaa gctgcctgga gcctttattc ttggagcagg agcaggtcca tttcagactc 420

tcgggttcaa ttctgagttt atgccagtta ttcagacaga aagtgaacac aagcctcctg 480

gtaaatggaa gttactttgc ccatgtgaac cctgcagatg gagggtgcct actggagaaa 540

tacagtgaga aatgtcatga ttttcagtgt gcattactgg ctaatctttt tgccagtgaa 600

ggccaacctg gcaaggtaat tgaggtgaaa gccaaaagaa gaactggacc acttaacttt 660

gtgacttgta tgagagagac cctggaaaaa cattatggaa ataagcctat aggaatggga 720

ggtactttca taattcagaa gggaaaagtg aagtctcaca ttatgcctgc agaattttct 780

tcctgcccct tgaactctga tgaagaagtg aataaatggt tgcattttta tgaaatgaaa 840

gctcctttgg tttgtctacc agtttttgtc tccagagacc cagggtttga tttgcgactg 900

gagcacactc atttttttag tcgtcatgga gaaggtggac actaccatta tgacactact 960

ccagatatag tggaatatct tggatacttc ttacctgcag agtttctcta tcgcattgat 1020

caaccaaaag agacgcattc aattgggcga gattaaatca gctgatactt atttagaaaa 1080

agaaataatt aaggttaatt aattgattga cttattaatt aatactgata taaaaccaat 1140

agaaatgatc ccacaggcca ggcacaatgg ctcatgccta tatcccagca ctttgggagg 1200

ctgaggcagg aagcacactg gagcccagga gtttgagacc agcttgggca acatagcaag 1260

accctgtcta tttttttaaa aaagtaaaaa atagaaatta tctcactact taaatcccat 1320

ttttttcact tcatatgaaa gaacatattg atagtatatt ctatattatt tcatagatct 1380

gtctgaaaga gattgggaac aaaaatatct aattgagata ttctttaatt ttttacatag 1440

cagctttatt ttttttattc tgtagtatca gcgaaatcag tcatgtttat accttgaata 1500

taaatatcag gaatcatgca attatttcta ctatgtattt agtagtatct tatatttgta 1560

taacattatt acattttgca aattagtatc acaactgcta agtagatgtt tctgagtatt 1620

agaaaaatca gtgttattac ctgcaggata ttaaaaaaca tttgaaaaag agaaaaagaa 1680

aaatcagtgt ttagaaatgt tgatagttat tgaatctttg aattgaattt taaaaatcca 1740

ttctagtaat cagagtatac tttttttata gaacaaggtg gcaggtgggg agccctttac 1800

ccttctggtg aagttaaacc atagaagttt acaatttgcc tttcacaaac attagcagtc 1860

cgggcatggt ggctgaagcc tgtgatccca gcatgttggg aggccgagtg ggaggattgc 1920

ctgagcctag gagtttaaac cagcctgggc accatggtga gaccccatct ctattattta 1980

aaatgtttct taaataaaaa aaacacaaac attagcaact agttggctag ccataattcc 2040

tcccttgttt cgattgccag ttagaagcaa tttttatttc actggttatt tgcaagagaa 2100

ggggtaaaaa aacagcatca gagtgcaaca ctgaagtgag cttactttaa tttgtaagtg 2160

aagctgttgc tgaacatgac cactatcgtt gctgaaatat aaaattatac tcactgattg 2220

taatggttga aattttcctg aataatcatt agccaaagat caactctcta atggtgctaa 2280

tggcaatcta gctaatgtgc aaatttagga agtcttcagt actaagtaca taattttcaa 2340

ataatatttt ttaattgtct actttggatg ttagctatgt cttgtgagta taaattccaa 2400

ttttaagcac tattttgatg caaaaaaatg aataaaaaat ttaatttatg aaaaaaaaaa 2460

aaaaaaaaaa a 2471

<210>17

<211>2471

<212>DNA

＜213〉homo sapiens (Homo sapiens)

<220>

<221>CDS

<222>(108)..(545)

<223>

<400>17

gttcgtttag aacagaaact gttcatactt ggtgcgctgt ggactcttgt gataattaac 60

caagagtagc tctatttgtc caacctcaca cctaaagaag aaagaaa atg gct tgt 116

Met Ala Cys

1

gct gag ttt tct ttt cat gta cca agt ctt gaa gag ctt gct gga gtt 164

Ala Glu Phe Ser Phe His Val Pro Ser Leu Glu Glu Leu Ala Gly Val

5 10 15

atg cag aag ggg tta aaa gat aac ttt gct gat gtc cag gtc tct gta 212

Met Gln Lys Gly Leu Lys Asp Asn Phe Ala Asp Val Gln Val Ser Val

20 25 30 35

gtt gat tgc cct gat ttg act aag gaa ccc ttt acc ttt cct gta aaa 260

Val Asp Cys Pro Asp Leu Thr Lys Glu Pro Phe Thr Phe Pro Val Lys

40 45 50

ggc atc tgt ggg aaa act aga att gca gaa gtt gga ggt gtg cct tac 308

Gly Ile Cys Gly Lys Thr Arg Ile Ala Glu Val Gly Gly Val Pro Tyr

55 60 65

tta ttg cct ctt gta aac caa aaa aaa gtt tat gat ctg aat aaa att 356

Leu Leu Pro Leu Val Asn Gln Lys Lys Val Tyr Asp Leu Asn Lys Ile

70 75 80

gca aaa gaa atc aag ctg cct gga gcc ttt att ctt gga gca gga gca 404

Ala Lys Glu Ile Lys Leu Pro Gly Ala Phe Ile Leu Gly Ala Gly Ala

85 90 95

ggt cca ttt cag act ctc ggg ttc aat tct gag ttt atg cca gtt att 452

Gly Pro Phe Gln Thr Leu Gly Phe Asn Ser Glu Phe Met Pro Val Ile

100 105 110 115

cag aca gaa agt gaa cac aag cct cct ggt aaa tgg aag tta ctt tgc 500

Gln Thr Glu Ser Glu His Lys Pro Pro Gly Lys Trp Lys Leu Leu Cys

120 125 130

cca tgt gaa ccc tgc aga tgg agg gtg cct act gga gaa ata cag 545

Pro Cys Glu Pro Cys Arg Trp Arg Val Pro Thr Gly Glu Ile Gln

135 140 145

tgagaaatgt catgattttc agtgtgcatt actggctaat ctttttgcca gtgaaggcca 605

acctggcaag gtaattgagg tgaaagccaa aagaagaact ggaccactta actttgtgac 665

ttgtatgaga gagaccctgg aaaaacatta tggaaataag cctataggaa tgggaggtac 725

tttcataatt cagaagggaa aagtgaagtc tcacattatg cctgcagaat tttcttcctg 785

ccccttgaac tctgatgaag aagtgaataa atggttgcat ttttatgaaa tgaaagctcc 845

tttggtttgt ctaccagttt ttgtctccag agacccaggg tttgatttgc gactggagca 905

cactcatttt tttagtcgtc atggagaagg tggacactac cattatgaca ctactccaga 965

tatagtggaa tatcttggat acttcttacc tgcagagttt ctctatcgca ttgatcaacc 1025

aaaagagacg cattcaattg ggcgagatta aatcagctga tacttattta gaaaaagaaa 1085

taattaaggt taattaattg attgacttat taattaatac tgatataaaa ccaatagaaa 1145

tgatcccaca ggccaggcac aatggctcat gcctatatcc cagcactttg ggaggctgag 1205

gcaggaagca cactggagcc caggagtttg agaccagctt gggcaacata gcaagaccct 1265

gtctattttt ttaaaaaagt aaaaaataga aattatctca ctacttaaat cccatttttt 1325

tcacttcata tgaaagaaca tattgatagt atattctata ttatttcata gatctgtctg 1385

aaagagattg ggaacaaaaa tatctaattg agatattctt taatttttta catagcagct 1445

ttattttttt tattctgtag tatcagcgaa atcagtcatg tttatacctt gaatataaat 1505

atcaggaatc atgcaattat ttctactatg tatttagtag tatcttatat ttgtataaca 1565

ttattacatt ttgcaaatta gtatcacaac tgctaagtag atgtttctga gtattagaaa 1625

aatcagtgtt attacctgca ggatattaaa aaacatttga aaaagagaaa aagaaaaatc 1685

agtgtttaga aatgttgata gttattgaat ctttgaattg aattttaaaa atccattcta 1745

gtaatcagag tatacttttt ttatagaaca aggtggcagg tggggagccc tttacccttc 1805

tggtgaagtt aaaccataga agtttacaat ttgcctttca caaacattag cagtccgggc 1865

atggtggctg aagcctgtga tcccagcatg ttgggaggcc gagtgggagg attgcctgag 1925

cctaggagtt taaaccagcc tgggcaccat ggtgagaccc catctctatt atttaaaatg 1985

tttcttaaat aaaaaaaaca caaacattag caactagttg gctagccata attcctccct 2045

tgtttcgatt gccagttaga agcaattttt atttcactgg ttatttgcaa gagaaggggt 2105

aaaaaaacag catcagagtg caacactgaa gtgagcttac tttaatttgt aagtgaagct 2165

gttgctgaac atgaccacta tcgttgctga aatataaaat tatactcact gattgtaatg 2225

gttgaaattt tcctgaataa tcattagcca aagatcaact ctctaatggt gctaatggca 2285

atctagctaa tgtgcaaatt taggaagtct tcagtactaa gtacataatt ttcaaataat 2345

attttttaat tgtctacttt ggatgttagc tatgtcttgt gagtataaat tccaatttta 2405

agcactattt tgatgcaaaa aaatgaataa aaaatttaat ttatgaaaaa aaaaaaaaaa 2465

aaaaaa 2471

<210>18

<211>146

<212>PRT

＜213〉homo sapiens (Homo sapiens)

<400>18

Met Ala Cys Ala Glu Phc Ser Phe His Val Pro Ser Leu Glu Glu Leu

1 5 10 15

Ala Gly Val Met Gln Lys Gly Leu Lys Asp Asn Phe Ala Asp Val Gln

20 25 30

Val Ser Val Val Asp Cys Pro Asp Leu Thr Lys Glu Pro Phe Thr Phe

35 40 45

Pro Val Lys Gly Ile Cys Gly Lys Thr Arg Ile Ala Glu Val Gly Gly

50 55 60

Val Pro Tyr Leu Leu Pro Leu Val Asn Gln Lys Lys Val Tyr Asp Leu

65 70 75 80

Asn Lys Ile Ala Lys Glu Ile Lys Leu Pro Gly Ala Phe Ile Leu Gly

85 90 95

Ala Gly Ala Gly Pro Phe Gln Thr Leu Gly Phe Asn Ser Glu Phe Met

100 105 110

Pro Val Ile Gln Thr Glu Ser Glu His Lys Pro Pro Gly Lys Trp Lys

115 120 125

Leu Leu Cys Pro Cys Glu Pro Cys Arg Trp Arg Val Pro Thr Gly Glu

130 135 140

Ile Gln

145

<210>19

<211>1934

<212>DNA

＜213〉homo sapiens (Homo sapiens)

<400>19

gcccttgtgg gggcgctgca ctggggatcc tcatggtctt cggcctggca cccgcccagg 60

ggctgagaca gtggctgccc tagagggacg cccgattctg cccatgtgct ccgctgtctc 120

ttgggggtct gagtagtggg gggttccctg ggtagaagag tcaagctggg gagcacgctg 180

gaggggaggc cttctctatc ctggtgccca gccagtgggc tggcctccca aggagggttg 240

actttgtgtg tgtctgggag gctgtgccag ccgggaggct gtgcctctgt cctctagggg 300

agctgggaaa acactggggc tggaagcatc agatgcataa gatagagtta ggtttaaaat 360

gattgcctgg taactgtgaa cagcagatgg gagggtggcc aagactggag gaggcagccc 420

cccttaggag cctgtgtcag ctgtgcaggg ggtggaggtt ggcctggtct agggggtaac 480

aaagcagacg ggaaagcagc acgggggtcc tcctggcaga ctgtggggaa tggttgcgct 540

agccacaggg actatttaag taaaattaaa aattgaatgg caatatttcc cttcctttta 600

aaactacctt gttcggttga tacttagtaa ctccgtggcc agttgaagcg ctggatgttt 660

cctagaacaa gaaccaccaa agcctgttcg cacagaaggg cgaccttgca gggactcgcc 720

gccgcgacct cagtgtggct tttacaggac tccccccgag catcagcagg gaccccggcg 780

gacgtgggcg ggcgcgcgtg agctcgggct gcccggccgg gcgtgcgggc ggggacatgg 840

taacctggtc cacggagggc ggccgccacc ctcgcgtagc tttcctgtgg ttttccagga 900

ctgtccggta cagcccgggc tccgcgtgcc ccgcccgctg gagcacacct gccaccgagg 960

cgcgcgtggg gccactgccg tggcggcggc tgccctcctc acactcggct ccgcgccgcc 1020

tccggccacc gtgcgctccc gcgtggggcg cctcggacgg gcccgggagg gctgggggct 1080

cttccccgga ggaagcggcc tccgcttcgc tggcgccgcc tttttagctt ggacttcagt 1140

cctccctcgg ggactcacct ccggagtaaa cggctcttca ttagcttgga gtggccgcag 1200

gtcccgtgac cagcacccgc gagaccctgt gcgacagctg ggctgatgct ccgtttctct 1260

gggaattggt gattttttac tgtgaagatg aaattaccct aatagcatga agatcgtggg 1320

tctgtgtgtc cgtgaagtga gtcccgtctg ccaggagctg acgaaccacg aatgcttctg 1380

cctgtgctgt gcattcccgg gcccgcagct cccggtcgag gggactccga tgtgaatttg 1440

ttgtgaattt gttgtgccac aatagcagtt ctggaatgaa gctaggaaac tcgagtgtgc 1500

tttttgttta atgagcgttc accaagctga gccggagcca tcctttcggt ggtagttggg 1560

gaaggctatg cagatttgct ctgttgtgac gcgttggtga cggtgcccag cctgcggttc 1620

cccacagcat cgcaggcgct cggaaatcct ctcccgtgcc tttagaggaa ggagaggatt 1680

cctcaggaat gcagggacgc ctgtttctgt cctcacacca cagaaaaaaa cctgagggaa 1740

aaatgagacg tgaggttcct gatttaagaa gcctgggttt ttttcatggt ggggggccat 1800

ttggaatgac agcctcactt ccttttgatg gctacatctg gatacttttc ctccctgtgt 1860

ttaatgtttc cctagggaga ggaaataaag cagaaggaac gtgttaaaaa aaaaaaaaaa 1920

aaaaaaaaaa aaaa 1934

<210>20

<211>1934

<212>DNA

＜213〉homo sapiens (Homo sapicns)

<220>

<221>CDS

<222>(837)..(1124)

<223>

<400>20

gcccttgtgg gggcgctgca ctggggatcc tcatggtctt cggcctggca cccgcccagg 60

ggctgagaca gtggctgccc tagagggacg cccgattctg cccatgtgct ccgctgtctc 120

ttgggggtct gagtagtggg gggttccctg ggtagaagag tcaagctggg gagcacgctg 180

gaggggaggc cttctctatc ctggtgccca gccagtgggc tggcctccca aggagggttg 240

actttgtgtg tgtctgggag gctgtgccag ccgggaggct gtgcctctgt cctctagggg 300

agctgggaaa acactggggc tggaagcatc agatgcataa gatagagtta ggtttaaaat 360

gattgcctgg taactgtgaa cagcagatgg gagggtggcc aagactggag gaggcagccc 420

cccttaggag cctgtgtcag ctgtgcaggg ggtggaggtt ggcctggtct agggggtaac 480

aaagcagacg ggaaagcagc acgggggtcc tcctggcaga ctgtggggaa tggttgcgct 540

agccacaggg actatttaag taaaattaaa aattgaatgg caatatttcc cttcctttta 600

aaactacctt gttcggttga tacttagtaa ctccgtggcc agttgaagcg ctggatgttt 660

cctagaacaa gaaccaccaa agcctgttcg cacagaaggg cgaccttgca gggactcgcc 720

gccgcgacct cagtgtggct tttacaggac tccccccgag catcagcagg gaccccggcg 780

gacgtgggcg ggcgcgcgtg agctcgggct gcccggccgg gcgtgcgggc ggggac atg 839

Met

1

gta acc tgg tcc acg gag ggc ggc cgc cac cct cgc gta gct ttc ctg 887

Val Thr Trp Ser Thr Glu Gly Gly Arg His Pro Arg Val Ala Phe Leu

5 10 15

tgg ttt tcc agg act gtc cgg tac agc ccg ggc tcc gcg tgc ccc gcc 935

Trp Phe Ser Arg Thr Val Arg Tyr Ser Pro Gly Ser Ala Cys Pro Ala

20 25 30

cgc tgg agc aca cct gcc acc gag gcg cgc gtg ggg cca ctg ccg tgg 983

Arg Trp Ser Thr Pro Ala Thr Glu Ala Arg Val Gly Pro Leu Pro Trp

35 40 45

cgg cgg ctg ccc tcc tca cac tcg gct ccg cgc cgc ctc cgg cca ccg 1031

Arg Arg Leu Pro Ser Ser His Ser Ala Pro Arg Arg Leu Arg Pro Pro

50 55 60 65

tgc gct ccc gcg tgg ggc gcc tcg gac ggg ccc ggg agg gct ggg ggc 1079

Cys Ala Pro Ala Trp Gly Ala Ser Asp Gly Pro Gly Arg Ala Gly Gly

70 75 80

tct tcc ccg gag gaa gcg gcc tcc gct tcg ctg gcg ccg cct ttt 1124

Ser Ser Pro Glu Glu Ala Ala Ser Ala Ser Leu Ala Pro Pro Phe

85 90 95

tagcttggac ttcagtcctc cctcggggac tcacctccgg agtaaacggc tcttcattag 1184

cttggagtgg ccgcaggtcc cgtgaccagc acccgcgaga ccctgtgcga cagctgggct 1244

gatgctccgt ttctctggga attggtgatt ttttactgtg aagatgaaat taccctaata 1304

gcatgaagat cgtgggtctg tgtgtccgtg aagtgagtcc cgtctgccag gagctgacga 1364

accacgaatg cttctgcctg tgctgtgcat tcccgggccc gcagctcccg gtcgagggga 1424

ctccgatgtg aatttgttgt gaatttgttg tgccacaata gcagttctgg aatgaagcta 1484

ggaaactcga gtgtgctttt tgtttaatga gcgttcacca agctgagccg gagccatcct 1544

ttcggtggta gttggggaag gctatgcaga tttgctctgt tgtgacgcgt tggtgacggt 1604

gcccagcctg cggttcccca cagcatcgca ggcgctcgga aatcctctcc cgtgccttta 1664

gaggaaggag aggattcctc aggaatgcag ggacgcctgt ttctgtcctc acaccacaga 1724

aaaaaacctg agggaaaaat gagacgtgag gttcctgatt taagaagcct gggttttttt 1784

catggtgggg ggccatttgg aatgacagcc tcacttcctt ttgatggcta catctggata 1844

cttttcctcc ctgtgtttaa tgtttcccta gggagaggaa ataaagcaga aggaacgtgt 1904

taaaaaaaaa aaaaaaaaaa aaaaaaaaaa 1934

<210>2l

<211>96

<212>PRT

＜213〉homo sapiens (Homo sapicns)

<400>21

Met Val Thr Trp Ser Thr Glu Gly Gly Arg His Pro Arg Val Ala Phe

1 5 10 15

Leu Trp Phe Ser Arg Thr Val Arg Tyr Ser Pro Gly Ser Ala Cys Pro

20 25 30

Ala Arg Trp Ser Thr Pro Ala Thr Glu Ala Arg Val Gly Pro Leu Pro

35 40 45

Trp Arg Arg Leu Pro Ser Ser His Ser Ala Pro Arg Arg Leu Arg Pro

50 55 60

Pro Cys Ala Pro Ala Trp Gly Ala Ser Asp Gly Pro Gly Arg Ala Gly

65 70 75 80

Gly Ser Ser Pro Glu Glu Ala Ala Ser Ala Ser Leu Ala Pro Pro Phe

85 90 95

<210>22

<211>1915

<212>DNA

＜213〉homo sapiens (Homo sapicns)

<400>22

gcacagggtg gcagcaggga aaaaaattag aaaagggtga aagattggga cttaacactt 60

cagggaagtc agctgccggg gagaaacttg ctcctaaatg aacacataag tttagatcgc 120

aatgaggagt agcagggtag ctggttgcta gagttacggt ggggatcaga aactcttcca 180

aacattttag cactgaggct ggggtagctt ttggcttttc ccaggtctca ggaggtggcc 240

tgagtcagca cacatcttcc cactcggtag acaggctggc ctctccctca ctttgagact 300

ttggcaactc ctgggccaca cggcctgcct ctttgattac taatgattgt cagtgactca 360

gagcttcctg ggacttcggg tacccacccg ctgttctcca tgcaaacaaa gcgccaggga 420

aatgacccac agggatcgca gctgcaggga gggccaggga ggttgggggt gggagtgaat 480

gctaaaagca gatcgtccag tgcccttttc agtgctaccg gcctctcacc aagcagtcct 540

ccatgtgagc aaccccgaga caaaaatgct aagtgggatc aagagagcag cactcggaga 600

gggtgtttgc cagtctgagt gtcccgcggt gcccgccaac ccgcttcctg actgacctga 660

gcaaggtctt actaagcagt cccatctctg tgggaggcat gcaacgcgtg cagggagttc 720

aggtgccggt cggcgtagcc aggcctggag gccccccagg caggaggccg cccaaaggcg 780

gggccggcgt ctcgcagact aggggctggg ggcggccaca gacggcctcg aaaccacagc 840

ccttacccca atcccacgag ccccgccaac gaaccacagg tgctgggctt tagagaacat 900

gggaaggcgg ccccagacct ggcgggaacg cctttccctc agagccaggc cccggccccg 960

tctgggaagc tcatcttgcg aagctgaggg agctcagggc aaaggccagg ctagcgcgga 1020

ccggaagggg ccgaggctgc acgggcctct gccagaacgc tcaggacatc ccggcctggg 1080

tttacaacgc tgttaggaaa attaaccaat gaataaagca acgttcagtg cgcagggagt 1140

gaaattcaat gcccaccgct aggctcctcg ctgcctctca ctcaagaggc ccaaactcag 1200

acggcgtcag ggacccggac ccagcagccg tttcacgcca atagataggg cgcatgcgca 1260

gaaatcctcc tcggctctct agcgtgagct ttcccaaggg gccacgccca gcttgccttc 1320

tgattggtcc agctggtggg gttgtcttcc gccatctttg atcagggcac taaggatgct 1380

ccccacggcc ttcacagtga cggcggagac cctgccccgc cagctgctca gtacgtgccg 1440

cgtagcccgt gcgagccaag tgtgagtccg ggcgagcgcc tgcggagcta gcactgggcc 1500

cagaatgaga gggaggcgga ggagcagcga tcacgtggtt ttagggactg tctaataatt 1560

ccacgccagc attgccggtg tttcaggggg tgggaaccgc tgcgttcccc atcaactttt 1620

ctcccaccca ccaccctccc caacctacaa gcccagctca gcttgaggta actgctgacc 1680

ggactgtcct atacagccct acaagacaga cggcgcctag ggctgaaagc gggggcctcc 1740

gtagggagcc agcgggggcc tcaatagtta ctcattttct ctacctttga tgaaaataag 1800

agctaattct taataaggct accgggtatc acgcaaaaac cctgtgctta ctattacact 1860

ttgggttgtt gcaaagatta aaggaaataa gccgtgcaaa aaaaaaaaaa aaaaa 1915

<210>23

<211>1915

<212>DNA

＜213〉homo sapiens (Homo sapiens)

<220>

<221>CDS

<222>(343)..(615)

<223>

<400>23

gcacagggtg gcagcaggga aaaaaattag aaaagggtga aagattggga cttaacactt 60

cagggaagtc agctgccggg gagaaacttg ctcctaaatg aacacataag tttagatcgc 120

aatgaggagt agcagggtag ctggttgcta gagttacggt ggggatcaga aactcttcca 180

aacattttag cactgaggct ggggtagctt ttggcttttc ccaggtctca ggaggtggcc 240

tgagtcagca cacatcttcc cactcggtag acaggctggc ctctccctca ctttgagact 300

ttggcaactc ctgggccaca cggcctgcct ctttgattac ta atg att gtc agt 354

Met Ile Val Ser

1

gac tca gag ctt cct ggg act tcg ggt acc cac ccg ctg ttc tcc atg 402

Asp Ser Glu Leu Pro Gly Thr Ser Gly Thr His Pro Leu Phe Ser Met

5 10 15 20

caa aca aag cgc cag gga aat gac cca cag gga tcg cag ctg cag gga 450

Gln Thr Lys Arg Gln Gly Asn Asp Pro Gln Gly Ser Gln Leu Gln Gly

25 30 35

ggg cca ggg agg ttg ggg gtg gga gtg aat gct aaa agc aga tcg tcc 498

Gly Pro Gly Arg Leu Gly Val Gly Val Asn Ala Lys Ser Arg Ser Ser

40 45 50

agt gcc ctt ttc agt gct acc ggc ctc tca cca agc agt cct cca tgt 546

Ser Ala Leu Phe Ser Ala Thr Gly Leu Ser Pro Ser Ser Pro Pro Cys

55 60 65

gag caa ccc cga gac aaa aat gct aag tgg gat caa gag agc agc act 594

Glu Gln Pro Arg Asp Lys Asn Ala Lys Trp Asp Gln Glu Ser Ser Thr

70 75 80

cgg aga ggg tgt ttg cca gtc tgagtgtccc gcggtgcccg ccaacccgct 645

Arg Arg Gly Cys Leu Pro Val

85 90

tcctgactga cctgagcaag gtcttactaa gcagtcccat ctctgtggga ggcatgcaac 705

gcgtgcaggg agttcaggtg ccggtcggcg tagccaggcc tggaggcccc ccaggcagga 765

ggccgcccaa aggcggggcc ggcgtctcgc agactagggg ctgggggcgg ccacagacgg 825

cctcgaaacc acagccctta ccccaatccc acgagccccg ccaacgaacc acaggtgctg 885

ggctttagag aacatgggaa ggcggcccca gacctggcgg gaacgccttt ccctcagagc 945

caggccccgg ccccgtctgg gaagctcatc ttgcgaagct gagggagctc agggcaaagg 1005

ccaggctagc gcggaccgga aggggccgag gctgcacggg cctctgccag aacgctcagg 1065

acatcccggc ctgggtttac aacgctgtta ggaaaattaa ccaatgaata aagcaacgtt 1125

cagtgcgcag ggagtgaaat tcaatgccca ccgctaggct cctcgctgcc tctcactcaa 1185

gaggcccaaa ctcagacggc gtcagggacc cggacccagc agccgtttca cgccaataga 1245

tagggcgcat gcgcagaaat cctcctcggc tctctagcgt gagctttccc aaggggccac 1305

gcccagcttg ccttctgatt ggtccagctg gtggggttgt cttccgccat ctttgatcag 1365

ggcactaagg atgctcccca cggccttcac agtgacggcg gagaccctgc cccgccagct 1425

gctcagtacg tgccgcgtag cccgtgcgag ccaagtgtga gtccgggcga gcgcctgcgg 1485

agctagcact gggcccagaa tgagagggag gcggaggagc agcgatcacg tggttttagg 1545

gactgtctaa taattccacg ccagcattgc cggtgtttca gggggtggga accgctgcgt 1605

tccccatcaa cttttctccc acccaccacc ctccccaacc tacaagccca gctcagcttg 1665

aggtaactgc tgaccggact gtcctataca gccctacaag acagacggcg cctagggctg 1725

aaagcggggg cctccgtagg gagccagcgg gggcctcaat agttactcat tttctctacc 1785

tttgatgaaa ataagagcta attcttaata aggctaccgg gtatcacgca aaaaccctgt 1845

gcttactatt acactttggg ttgttgcaaa gattaaagga aataagccgt gcaaaaaaaa 1905

aaaaaaaaaa 1915

<210>24

<211>91

<212>PRT

＜213〉homo sapiens (Homo sapiens)

<400>24

Met Ile Val Ser Asp Ser Glu Leu Pro Gly Thr Ser Gly Thr His Pro

1 5 10 15

Leu Phe Ser Met Gln Thr Lys Arg Gln Gly Asn Asp Pro Gln Gly Ser

20 25 30

Gln Leu Gln Gly Gly Pro Gly Arg Leu Gly Val Gly Val Asn Ala Lys

35 40 45

Ser Arg Ser Ser Ser Ala Leu Phe Ser Ala Thr Gly Leu Ser Pro Ser

50 55 60

Ser Pro Pro Cys Glu Gln Pro Arg Asp Lys Asn Ala Lys Trp Asp Gln

65 70 75 80

Glu Ser Ser Thr Arg Arg Gly Cys Leu Pro Val

85 90

<210>25

<211>1575

<212>DNA

＜213〉homo sapiens (Homo sapiens)

<400>25

gcacacaggc agtgggtacg gcagactggg gttggtggca tggcccagga ccccacgctg 60

actagtgagc ccctccgcag gcatagcgtg gcgtcagccc agctgcagga gaagctggca 120

ggagcccagc gccagctggg gcagctccgg gctcaggaag ccggcctgca gcaggagcag 180

aggaaggcag acacccacaa gaagatgact gagttctaga gaccccacaa gcactatgga 240

cgaagcgtgg gaccccagca cgggctgccc tcaggaagac cagtgttgcc cgaggagggg 300

ccggcctgct ggcctggggc gtgcggacac tgctgagtgg agacagagct gcggggtccc 360

atctggacac ttacttgccc acctgccagt gtcttgggca tttccttggc aaggacatta 420

aagtgatttc atcacagtgt cattcagtgg agatcagctg gctgcagggt ctctggggag 480

agaaggggcc tcggcttcac aggatggggc tgccagtgtc ctgggcccct cctgccctct 540

gggttctagg gtgctgcgcc ctgctcctct cgctgtgggc gctgtgcaca gcctgccgca 600

ggcccgagga cgctgtagcc cccaggaaga gggcgcggag gcagcgggcg aggctgcagg 660

gcagtgcgac ggcggcggaa gcgcaagtcg gacaccagac tgcacgagct gcaccggggc 720

ccgcgcagca gcagggccct gcggcctgcc agcatggatc tcctgcgccc acactggctg 780

gaggtgtcca gggacatcac cggaccgcag gcagccccct ctgccttccc acaccaggag 840

ctgccccggg ctctgccggc agctgcagcc accgcagggt gcgctggcct cgaggccacc 900

tattccaacg tggggctggc ggcccttccc ggggtcagcc tggcggccag ccctgtggtg 960

gccgagtatg cccgcgtcca gaagcgcaaa gggacccatc gcagtcccca agagccacag 1020

caggggaaga ctgaggtgac cccggccgct caggtggacg tcctgtactc cagggtctgc 1080

aagcctaaaa ggagggaccc aggacccacc acagacccgc tggaccccaa gggccaggga 1140

gcgattctgg ccctggcggg tgacctggcc taccagaccc tcccgctcag ggccctggat 1200

gtggacagcg gccccctgga aaacgtgtat gagagcatcc gggagctggg ggaccctgct 1260

ggcaggagca gcacgtgcgg ggctgggacg ccccctgctt ccagctgccc cagcctaggg 1320

aggggctgga gacccctccc tgcctccctg ccctgaacac tcaaggacct gtgctccttc 1380

ctccagagtg aggcccgtcc cccgccccgc cccgcctcac agctgacagc gccagtccca 1440

ggtccccggg ccgccagccc gtgaggtccg tgaggtcctg gccgctctga cagccgcggc 1500

ctccccgggc tccagagaag gcccgcgtct aaataaagcg ccagcgcagg atgaaaaaaa 1560

aaaaaaaaaa aaaaa 1575

<210>26

<211>1575

<212>DNA

＜213〉homo sapiens (Homo sapiens)

<220>

<221>CDS

<222>(754)..(1353)

<223>

<400>26

gcacacaggc agtgggtacg gcagactggg gttggtggca tggcccagga ccccacgctg 60

actagtgagc ccctccgcag gcatagcgtg gcgtcagccc agctgcagga gaagctggca 120

ggagcccagc gccagctggg gcagctccgg gctcaggaag ccggcctgca gcaggagcag 180

aggaaggcag acacccacaa gaagatgact gagttctaga gaccccacaa gcactatgga 240

cgaagcgtgg gaccccagca cgggctgccc tcaggaagac cagtgttgcc cgaggagggg 300

ccggcctgct ggcctggggc gtgcggacac tgctgagtgg agacagagct gcggggtccc 360

atctggacac ttacttgccc acctgccagt gtcttgggca tttccttggc aaggacatta 420

aagtgatttc atcacagtgt cattcagtgg agatcagctg gctgcagggt ctctggggag 480

agaaggggcc tcggcttcac aggatggggc tgccagtgtc ctgggcccct cctgccctct 540

gggttctagg gtgctgcgcc ctgctcctct cgctgtgggc gctgtgcaca gcctgccgca 600

ggcccgagga cgctgtagcc cccaggaaga gggcgcggag gcagcgggcg aggctgcagg 660

gcagtgcgac ggcggcggaa gcgcaagtcg gacaccagac tgcacgagct gcaccggggc 720

ccgcgcagca gcagggccct gcggcctgcc agc atg gat ctc ctg cgc cca cac 774

Met Asp Leu Leu Arg Pro His

1 5

tgg ctg gag gtg tcc agg gac atc acc gga ccg cag gca gcc ccc tct 822

Trp Leu Glu Val Ser Arg Asp Ile Thr Gly Pro Gln Ala Ala Pro Ser

10 15 20

gcc ttc cca cac cag gag ctg ccc cgg gct ctg ccg gca gct gca gcc 870

Ala Phe Pro His Gln Glu Leu Pro Arg Ala Leu Pro Ala Ala Ala Ala

25 30 35

acc gca ggg tgc gct ggc ctc gag gcc acc tat tcc aac gtg ggg ctg 918

Thr Ala Gly Cys Ala Gly Leu Glu Ala Thr Tyr Ser Asn Val Gly Leu

40 45 50 55

gcg gcc ctt ccc ggg gtc agc ctg gcg gcc agc cct gtg gtg gcc gag 966

Ala Ala Leu Pro Gly Val Ser Leu Ala Ala Ser Pro Val Val Ala Glu

60 65 70

tat gcc cgc gtc cag aag cgc aaa ggg acc cat cgc agt ccc caa gag 1014

Tyr Ala Arg Val Gln Lys Arg Lys Gly Thr His Arg Ser Pro Gln Glu

75 80 85

cca cag cag ggg aag act gag gtg acc ccg gcc gct cag gtg gac gtc 1062

Pro Gln Gln Gly Lys Thr Glu Val Thr Pro Ala Ala Gln Val Asp Val

90 95 100

ctg tac tcc agg gtc tgc aag cct aaa agg agg gac cca gga ccc acc 1110

Leu Tyr Ser Arg Val Cys Lys Pro Lys Arg Arg Asp Pro Gly Pro Thr

105 110 115

aca gac ccg ctg gac ccc aag ggc cag gga gcg att ctg gcc ctg gcg 1158

Thr Asp Pro Leu Asp Pro Lys Gly Gln Gly Ala Ile Leu Ala Leu Ala

120 125 130 135

ggt gac ctg gcc tac cag acc ctc ccg ctc agg gcc ctg gat gtg gac 1206

Gly Asp Leu Ala Tyr Gln Thr Leu Pro Leu Arg Ala Leu Asp Val Asp

140 145 150

agc ggc ccc ctg gaa aac gtg tat gag agc atc cgg gag ctg ggg gac 1254

Ser Gly Pro Leu Glu Asn Val Tyr Glu Ser Ile Arg Glu Leu Gly Asp

155 160 165

cct gct ggc agg agc agc acg tgc ggg gct ggg acg ccc cct gct tcc 1302

Pro Ala Gly Arg Ser Ser Thr Cys Gly Ala Gly Thr Pro Pro Ala Ser

170 175 180

agc tgc ccc agc cta ggg agg ggc tgg aga ccc ctc cct gcc tcc ctg 1350

Ser Cys Pro Ser Leu Gly Arg Gly Trp Arg Pro Leu Pro Ala Ser Leu

185 190 195

ccc tgaacactca aggacctgtg ctccttcctc cagagtgagg cccgtccccc 1403

Pro

200

gccccgcccc gcctcacagc tgacagcgcc agtcccaggt ccccgggccg ccagcccgtg 1463

aggtccgtga ggtcctggcc gctctgacag ccgcggcctc cccgggctcc agagaaggcc 1523

cgcgtctaaa taaagcgcca gcgcaggatg aaaaaaaaaa aaaaaaaaaa aa 1575

<210>27

<211>200

<212>PRT

＜213〉homo sapiens (Homo sapiens)

<400>27

Met Asp Leu Leu Arg Pro His Trp Leu Glu Val Ser Arg Asp Ile Thr

1 5 10 15

Gly Pro Gln Ala Ala Pro Ser Ala Phe Pro His Gln Glu Leu Pro Arg

20 25 30

Ala Leu Pro Ala Ala Ala Ala Thr Ala Gly Cys Ala Gly Leu Glu Ala

35 40 45

Thr Tyr Ser Asn Val Gly Leu Ala Ala Leu Pro Gly Val Ser Leu Ala

50 55 60

Ala Ser Pro Val Val Ala Glu Tyr Ala Arg Val Gln Lys Arg Lys Gly

65 70 75 80

Thr His Arg Ser Pro Gln Glu Pro Gln Gln Gly Lys Thr Glu Val Thr

85 90 95

Pro Ala Ala Gln Val Asp Val Leu Tyr Ser Arg Val Cys Lys Pro Lys

100 105 110

Arg Arg Asp Pro Gly Pro Thr Thr Asp Pro Leu Asp Pro Lys Gly Gln

115 120 125

Gly Ala Ile Leu Ala Leu Ala Gly Asp Leu Ala Tyr Gln Thr Leu Pro

130 135 140

Leu Arg Ala Leu Asp Val Asp Ser Gly Pro Leu Glu Asn Val Tyr Glu

145 150 155 160

Ser Ile Arg Glu Leu Gly Asp Pro Ala Gly Arg Ser Ser Thr Cys Gly

165 170 175

Ala Gly Thr Pro Pro Ala Ser Ser Cys Pro Ser Leu Gly Arg Gly Trp

180 185 190

Arg Pro Leu Pro Ala Ser Leu Pro

195 200

<210>28

<211>1800

<212>DNA

＜213〉homo sapiens (Homo sapiens)

<400>28

ggaatcctcg ggccgccttg tgaggggggt gttgctgtca tctccagggc taggtgacag 60

cttgttgcag gccccacagc cagggcctca gggatgggga tctggccatg tctgttttaa 120

gccgaacagg ctgttcttcc atgtggagtc tccctccgtg atcccctggg gtcaagtcct 180

gacggctggg ttcgctccct cagtgactcc gacagctctt gtctcagagg tgctggggtg 240

aaggctgtgt ggggccaggc ccctggggtc agacttcttg ccccttctgc ccgggggacg 300

ctctgggctc agggtggggc cagacagcta catcacaggg acacttgtta tgggtcgggg 360

tccagggagc acccagccag tggagtgttg gaggccactg agagggacat gactgcggtg 420

tccgagcagc gtcgtggcca ccctgtgtgc ccactccctg gtggacagac ctacgtcacc 480

tggggattgc agagcaaaag gagtgctgtt ggggtgtgtg aggtttgggg ttctgtttct 540

tgctgtgaat tgggtcatga cctgtgtcgg agcgttctct ggcctccact tgcccctgca 600

gaccagggtg tctggagggt tgtcgggggc ttgatggagg aattgctgac cacaccatgc 660

aggaagaggt gggtcccagg gacacaggaa ctttggggtc agccggttcc agattcagtt 720

gcagaggagc atcccccttg cttagccagg gaggggaagc cctcttctca cacccggcct 780

gggtatgttg tgggagagtc atttcccagg aggaaatggg gactgttacc gggggagggg 840

gtgctgtccc caggcagcag caagcgtccc ttacgcttgg gctgtccgag accctgctgc 900

tctaggcggt tgtgatgggg gagccccaca gggcacagag agccagctga aggcggcagc 960

tctgggtggg atcacatgga aaggggaggc gagccgagcc tccctcttgc caatcttggt 1020

ctccccacag ggtcatagct cctgggcccc tcacttgtca gaccctccat tcaccaaatt 1080

aaggataagt ttcacgattt cgcactccag cctggtgacg aagtgagact ccatctcaaa 1140

aaataaataa ataaataaaa ataaacctca ctgtttgttt taacaataac aagcgtggta 1200

agggtggtgt cagtccataa gttagatagg cagttgctag gcagatgtcg ttgcagatgt 1260

gtgtgtgtgt gtgtgttgtg tttaaggttg tggtggcctt tgtgcaggtt gtaaattttt 1320

gtagtctttt gatagttctt gttatcaacc atatgtacat gagaaccctt cccccttcat 1380

ggcgtttcct ggctccgttt gccagggttt taatacgagt gactccattt tgaatctgac 1440

aactttcaca tttccccttt tgatcaaggt ctttctcaaa agcatcactg atcaatcatc 1500

ctgtatttag gttttgatat ctcttggtgc cagtctgccc tcatgttgaa gggagtcact 1560

ggtaactagg aattagcatc aaaacccttt agccacattt gaacaacaaa agaggtttgg 1620

agggagtgga tctcaggcta agtctacctg gagtccactg ttaagttcaa ttctgtctgt 1680

tccataggca ctgtctatca tctcaaagtg ctgggagagc attattctct taggagttgc 1740

atttctatgc aaatttgaca agaaacaggt ataaagttct taaaaaaaaa aaaaaaaaaa 1800

<210>29

<211>1800

<212>DNA

＜213〉homo sapiens (Homo sapiens)

<220>

<221>CDS

<222>(409)..(912)

<223>

<400>29

ggaatcctcg ggccgccttg tgaggggggt gttgctgtca tctccagggc taggtgacag 60

cttgttgcag gccccacagc cagggcctca gggatgggga tctggccatg tctgttttaa 120

gccgaacagg ctgttcttcc atgtggagtc tccctccgtg atcccctggg gtcaagtcct 180

gacggctggg ttcgctccct cagtgactcc gacagctctt gtctcagagg tgctggggtg 240

aaggctgtgt ggggccaggc ccctggggtc agacttcttg ccccttctgc ccgggggacg 300

ctctgggctc agggtggggc cagacagcta catcacaggg acacttgtta tgggtcgggg 360

tccagggagc acccagccag tggagtgttg gaggccactg agagggac atg act gcg 417

Met Thr Ala

1

gtg tcc gag cag cgt cgt ggc cac cct gtg tgc cca ctc cct ggt gga 465

Val Ser Glu Gln Arg Arg Gly His Pro Val Cys Pro Leu Pro Gly Gly

5 10 15

cag acc tac gtc acc tgg gga ttg cag agc aaa agg agt gct gtt ggg 513

Gln Thr Tyr Val Thr Trp Gly Leu Gln Ser Lys Arg Ser Ala Val Gly

20 25 30 35

gtg tgt gag gtt tgg ggt tct gtt tct tgc tgt gaa ttg ggt cat gac 561

Val Cys Glu Val Trp Gly Ser Val Ser Cys Cys Glu Leu Gly His Asp

40 45 50

ctg tgt cgg agc gtt ctc tgg cct cca ctt gcc cct gca gac cag ggt 609

Leu Cys Arg Ser Val Leu Trp Pro Pro Leu Ala Pro Ala Asp Gln Gly

55 60 65

gtc tgg agg gtt gtc ggg ggc ttg atg gag gaa ttg ctg acc aca cca 657

Val Trp Arg Val Val Gly Gly Leu Met Glu Glu Leu Leu Thr Thr Pro

70 75 80

tgc agg aag agg tgg gtc cca ggg aca cag gaa ctt tgg ggt cag ccg 705

Cys Arg Lys Arg Trp Val Pro Gly Thr Gln Glu Leu Trp Gly Gln Pro

85 90 95

gtt cca gat tca gtt gca gag gag cat ccc cct tgc tta gcc agg gag 753

Val Pro Asp Ser Val Ala Glu Glu His Pro Pro Cys Leu Ala Arg Glu

100 105 110 115

ggg aag ccc tct tct cac acc cgg cct ggg tat gtt gtg gga gag tca 801

Gly Lys Pro Ser Ser His Thr Arg Pro Gly Tyr Val Val Gly Glu Ser

120 125 130

ttt ccc agg agg aaa tgg gga ctg tta ccg ggg gag ggg gtg ctg tcc 849

Phe Pro Arg Arg Lys Trp Gly Leu Leu Pro Gly Glu Gly Val Leu Ser

135 140 145

cca ggc agc agc aag cgt ccc tta cgc ttg ggc tgt ccg aga ccc tgc 897

Pro Gly Ser Ser Lys Arg Pro Leu Arg Leu Gly Cys Pro Arg Pro Cys

150 155 160

tgc tct agg cgg ttg tgatggggga gccccacagg gcacagagag ccagctgaag 952

Cys Ser Arg Arg Leu

165

gcggcagctc tgggtgggat cacatggaaa ggggaggcga gccgagcctc cctcttgcca 1012

atcttggtct ccccacaggg tcatagctcc tgggcccctc acttgtcaga ccctccattc 1072

accaaattaa ggataagttt cacgatttcg cactccagcc tggtgacgaa gtgagactcc 1132

atctcaaaaa ataaataaat aaataaaaat aaacctcact gtttgtttta acaataacaa 1192

gcgtggtaag ggtggtgtca gtccataagt tagataggca gttgctaggc agatgtcgtt 1252

gcagatgtgt gtgtgtgtgt gtgttgtgtt taaggttgtg gtggcctttg tgcaggttgt 1312

aaatttttgt agtcttttga tagttcttgt tatcaaccat atgtacatga gaacccttcc 1372

cccttcatgg cgtttcctgg ctccgtttgc cagggtttta atacgagtga ctccattttg 1432

aatctgacaa ctttcacatt tccccttttg atcaaggtct ttctcaaaag catcactgat 1492

caatcatcct gtatttaggt tttgatatct cttggtgcca gtctgccctc atgttgaagg 1552

gagtcactgg taactaggaa ttagcatcaa aaccctttag ccacatttga acaacaaaag 1612

aggtttggag ggagtggatc tcaggctaag tctacctgga gtccactgtt aagttcaatt 1672

ctgtctgttc cataggcact gtctatcatc tcaaagtgct gggagagcat tattctctta 1732

ggagttgcat ttctatgcaa atttgacaag aaacaggtat aaagttctta aaaaaaaaaa 1792

aaaaaaaa 1800

<210>30

<211>168

<212>PRT

＜213〉homo sapiens (Homo sapiens)

<400>30

Met Thr Ala Val Ser Glu Gln Arg Arg Gly His Pro Val Cys Pro Leu

1 5 10 15

Pro Gly Gly Gln Thr Tyr Val Thr Trp Gly Leu Gln Ser Lys Arg Ser

20 25 30

Ala Val Gly Val Cys Glu Val Trp Gly Ser Val Ser Cys Cys Glu Leu

35 40 45

Gly His Asp Leu Cys Arg Ser Val Leu Trp Pro Pro Leu Ala Pro Ala

50 55 60

Asp Gln Gly Val Trp Arg Val Val Gly Gly Leu Met Glu Glu Leu Leu

65 70 75 80

Thr Thr Pro Cys Arg Lys Arg Trp Val Pro Gly Thr Gln Glu Leu Trp

85 90 95

Gly Gln Pro Val Pro Asp Ser Val Ala Glu Glu His Pro Pro Cys Leu

100 105 110

Ala Arg Glu Gly Lys Pro Ser Ser His Thr Arg Pro Gly Tyr Val Val

115 120 125

Gly Glu Ser Phe Pro Arg Arg Lys Trp Gly Leu Leu Pro Gly Glu Gly

130 135 140

Val Leu Ser Pro Gly Ser Ser Lys Arg Pro Leu Arg Leu Gly Cys Pro

145 150 155 160

Arg Pro Cys Cys Ser Arg Arg Leu

165

<210>31

<211>20

<212>DNA

＜213〉primer

<400>31

ggccagc tcatggtatc tcc 20

<210>32

<211>21

<212>DNA

＜213〉primer

<400>32

atgaaccctc tgactccgtc c 21

<210>33

<211>20

<212>DNA

＜213〉primer

<400>33

cagaaacctg gggtaagcaa 20

<210>34

<211>22

<212>DNA

＜213〉primer

<400>34

tacaaatcac gggaaaagta cg 22

<210>35

<211>22

<212>DNA

＜213〉primer

<400>35

gatgatgctg ccaagttatt ca 22

<210>36

<211>22

<212>DNA

＜213〉primer

<400>36

atccccatag acatccttac cg 22

<210>37

<211>21

<212>DNA

＜213〉primer

<400>37

ctggagggag atcacaaaac a 21

<210>38

<211>22

<212>DNA

＜213〉primer

<400>38

atgaagcact ggtgggtgat ac 22

<210>39

<211>18

<212>DNA

＜213〉primer

<400>39

cccgtctggg atgtgagg 18

<210>40

<211>22

<212>DNA

＜213〉primer

<400>40

gctctttgtg ggttcttact ag 22

<210>41

<211>20

<212>DNA

＜213〉primer

<400>41

ttcatacttg gtgcgctgtg 20

<210>42

<211>19

<212>DNA

＜213〉primer

<400>42

gagggaacaa agctaacgg 19

<210>43

<211>19

<212>DNA

＜213〉primer

<400>43

gattctgccc atgtgctcc 19

<210>44

<211>22

<212>DNA

＜213〉primer

<400>44

tcctttattt cgtcttcctt gc 22

<210>45

<211>22

<212>DNA

＜213〉primer

<400>45

tagctggttg ctagagttac gg 22

<210>46

<211>20

<212>DNA

＜213〉primer

<400>46

tttcctttat tcggcacgtt 20

<210>47

<211>18

<212>DNA

＜213〉primer

<400>47

cggcagactg gggttggt 18

<210>48

<211>18

<212>DNA

＜213〉primer

<400>48

tttatttcgc ggtcgcgt 18

<210>49

<211>20

<212>DNA

＜213〉primer

<400>49

gggtgttgct gtcatctcca 20

<210>50

<211>20

<212>DNA

＜213〉primer

<400>50

ttctccaaac ctccctcacc 20

Claims (9)

1. isolating people's albumen with promotion 3T3 cell transformation function is characterized in that it has the aminoacid sequence of the group of being selected from down: SEQ ID NO:3,6,9,12,15,18,21,24,27,30.

2. albumen as claimed in claim 1 is characterized in that, this polypeptide has the aminoacid sequence of the group of being selected from down: SEQ ID NO:3,6,9,12,15,27,30.

3. isolating polynucleotide is characterized in that, it is selected from down group:

(a) the proteic according to claim 1 polynucleotide of coding;

(b) with polynucleotide (a) complementary polynucleotide.

4. polynucleotide as claimed in claim 3 is characterized in that, the albumen of this polynucleotide encoding has the aminoacid sequence of the group of being selected from down: SEQ ID NO:3,6,9,12,15,27,30.

5. polynucleotide as claimed in claim 3 is characterized in that, the sequence of these polynucleotide is selected from down group:

SEQ ID NO:2,5,8,11,14,17,20,23,26,29 coding region sequence or full length sequence.

6. a carrier is characterized in that, it contains the described polynucleotide of claim 3.

7. a genetically engineered host cell is characterized in that, it is a kind of host cell that is selected from down group:

(a) host cell that transforms or transduce with the described carrier of claim 6;

(b) host cell that transforms or transduce with the described polynucleotide of claim 3.

8. a claim 1 is described has a proteic preparation method of people who promotes 3T3 cell transformation function, it is characterized in that this method comprises:

(a) being fit to express under the proteic condition of people with promotion 3T3 cell transformation function, cultivate the described host cell of claim 7;

(b) from culture, isolate people's albumen with promotion 3T3 cell transformation function.

9. an energy and claim 1 are described has the people's protein-specific bonded antibody that promotes 3T3 cell transformation function.